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PREAMBLE 
In this thesis a number of rather diverging clinical observa-
tions is reported. They have one main theme in common: the occur-
rence of paradoxical responses of the hypophysis to hypothalamic 
releasing hormones. In 1975 we started to investigate the connec-
tion between the paradoxical growth hormone ( h G H ) , releasing 
actions of the two hypothalamic releasing hormones, luteinizing 
hormone releasing hormone (LRH) and thyrotropin releasing hormone 
(TRH) one the one hand and the hGH inhibitory effects of somato-
statin (SRIF) and bromocryptine on the other hand in patients 
wi th acromegaly ( 1 ) . 
Intrigued by the frequent occurrence of paradoxical responses 
of hGH to releasing hormones in acromegaly we wondered whether 
such paradoxical phenomena also would occur in other forms of 
hyperpi tui tari sm. 
At that time adolescents with tall stature, some of them under 
suspicion of pituitary gigantism were studied. We performed oral 
glucose loading tests to investigate hGH hypersecretion and its 
suppressibi1 ity in these subjects. To our surprise most of these 
youngsters showed paradoxical increases of circulating hGH during 
the test ( 2 ) . This serendipitously discovered phenomenon streng-
thened our interest in antinomous responses of pituitary hormones. 
In 1976 we started a study in patients with Cushing's disease. 
In some patients with this disorder - in contrast to normal sub-
jects - Cortisol levels appeared to rise after TRH and/or LRH 
administration ( 3 ) . When we later found that Cortisol responsive-
ness to TRH also occurs in healthy pregnant women we deduced from 
these data, and the scanty knowledge about the altered regulation of 
ACTH in pregnancy, an anatomical base for the paradoxical phenomena 
occurring in some of the patients with Cushing's disease ( 4 ) . 
After we had studied 23 patients with Cushing's disease - 9 TRH/ 
LRH responders and 14 TRH/LRH non-responders - we were able to 
systematically look for possible differences between both groups 
of patients. The outcome of these studies led us to reconsider our 
prior explanation for the occurrence of these paradoxical respon-
ses ( 5 ) . 
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CHAPTER I 
LITERATURE DATA ON THE SPECIFICITY OF HYPOTHALAMIC RELEASING 
HORMONES IN NORMAL AND PATHOLOGICAL CONDITIONS 
5 1 INTRODUCTION 
Knowledge of the functioning of the hypothalamic-pituitary 
system was increased greatly in recent years.In 1935 Houssay (1) 
reported that the blood flow between the hypothalamus and the pars 
distalis of the pituitary in the toad is directed downwards. Wis-
locki and King in 1936 (2) were the first to demonstrate similar 
circulatory relations in mammals such as the cat and the rhesus 
monkey. In 1954 Xuereb (3) found such a portal system in man. From 
this and other evidence it became clear that neurosecretory prod­
ucts of hypothalamic areas are transported by the blood to the 
pars distalis of the hypophysis (the adenohypophysis) to regulate 
the secretion of the various anterior pituitary hormones (4, 5 ) . 
By using extracts of hypothalami, a number of hypophysiotropiс 
factors were successively isolated. The first of these was cortico­
tropin releasing factor in 1955 by Saffran et al (6). Recently, 
the chemical structure of three releasing hormones was established 
and confirmed by synthesis: in 1968 thyrotropin releasing hormone 
(TRH) by the group of G u i l l e m m (7) later also called thyroliberin 
or prothyrelin, in 1971 luteinizing hormone releasing hormone 
(LHRH or LRH) also called LH-FSH-RH, or gonadoliberiη (GnRH) by 
the New Orleans group of Schally ( 8 ) , and in 1981 corticotropin 
releasing hormone (CRH) or, trivially corti col ι b e n η again by in­
vestigators of the Salk Institute of La Jolla ( 9 ) . Tentative chemi­
cal structures were presented for other releasing factors such as 
growth hormone releasing hormone (GHRH) or somatotropin releasing 
factor or somatoliberin, prolactin releasing factor (PRF) or lacto-
liberin, and melanotropin releasing factor (MRF) or mei anolι berin 
(10). 
Apart from hypothalamic releasing hormones and factors, a num­
ber of release inhibiting principles were discovered in the last 
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decade. Examples of these are prolactin release-inhibiting factor 
(PIF) or Lactostatin and growth hormone release-inhibiting factor. 
The chemical structure of the latter was established in 1973 by 
the La Jolla group (11) and since then named growth hormone release-
inhibiting hormone (GHRIH) or somatotropin release-inhibiting 
factor (SRIF) or trivially somatostatin. The structure formulas of 
the hypothalamic regulatory peptides used in this thesis, TRH, 
LHRH and somatostatin, are depicted in table 1. 
Table 1: CHEMICAL STRUCTURE OF THREE HYPOTHALAMIC REGULATORY 
PEPTIDES 
TRH 
LRH 
Glu - Pro - NH, 
0 
NH-, 
Glu 
Gly 
His 
Pro 
Tro - Ser 
Arg - Leu 
Туг 
Gly 
SRIF Ala - Gly 
OH 
Cys 
ι 
S 
ι 
S 
ι 
Cys 
Lys - Asn 
Thr - Phe 
Phe 
ι 
Trp 
ι 
Lys 
ι 
Thr 
In general the hypothalamic releasing hormones were proven so 
far to be rather specific in the stimulatory effect on their tro­
pic hypophyseal hormone, whereas the hypothalamic release inhibi­
ting peptides seem to have a rather broad or at least a less 
specific biological action. For example, somatostatin inhibits a 
wide variety of peptide hormones within and outside the hypophysis. 
Moreover, it has to be realized that this peptide occurs in a wide 
number of tissues, besides the central nervous system, such as the 
gastrointestinal tract, the pancreas, and the peripheral nervous 
system (12). 
i 2. SPECIFICITY OF HYPOTHALAMIC HORMONES IN NORMAL PHYSIOLOGY 
In healthy men,LRH exclusively stimulates the release of gona-
12 
dotropins, although follicle stimulating hormone (FSH) to a lesser 
degree than luteinizing hormone (LH) ( 1 3 ) . 
Similarly, TRH stimulates thyroid stimulating hormone (TSH) 
release but does not affect adrenocorticotropic hormone (ACTH), LH, 
FSH and human growth hormone (hGH) secretion (14). When pharmaco­
logical amounts of TRH are administered, prolactin is stimulated 
in addition. In patients suffering from severe primary hypothyroi­
dism, hyperprolactinaemia is sometimes found due to high endoge­
nous TRH activity; thus high levels of endogenous TRH may also 
stimulate prolactin release. However, the role of TRH as a prolac­
tin stimulatory agent under physiological circumstances, is still 
questionable (10). 
The inhibitory effect of SRIF in pharmacological amounts is not 
limited to the release of hGH. Exogenous SRIF has been reported to 
inhibit the secretion of numerous hormones of various organs: ACTH, 
prolactin, TSH, insulin, glucagon, vasoactive intestinal peptide, 
motilin, secretin, gastrin and renin (12). The specificity of endo­
genous hypothalamic SRIF in normal physiology is essentially un­
known. 
In hypothalamic pituitary disorders the specificity of the 
hypothalamic hormones may be altered. 
§ 3. THE SPECIFICITY OF HYPOTHALAMIC HORMONES IN PATHOLOGY. 
In this paragraph, special attention will be given to the spe­
cificity of exogenous TRH and LRH in the two pituitary disorders, 
which have been studied to some detail in this thesis: acromegaly 
and Cushi ng's di sease. 
ACROMEGALY 
In 1972 Irie et al (15) reported that 8 out of 11 patients 
with acromegaly showed an increase of hGH after TRH administration. 
In 1973 Rubin et al (16) found in 4 out of б patients with acrome­
galy that also LRH can stimulate growth hormone secretion. These 
findings were confirmed by many other investigators (17-23). A 
higher frequency of hGH responses is found after TRH (50 - 80%) 
compared to LRH (10 - 3 0 % ) . In a number of studies the effects of 
TRH and LRH were compared. In general, the response to TRH was 
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found to be more pronounced than to LRH. It is added however, that 
stringent molar dose response studies, to our knowledge, were never 
reported. 
It has to be noted, that such anomalous responses of plasma 
hGH levels in response to TRH administration were reported in a 
number of other disorders: diabetes mellitus ( 2 4 ) , anorexia nervosa 
( 2 5 ) , renal failure ( 2 6 ) , chronical liver disease ( 2 7 ) , primary 
hypothyroidism (28) and mental depression ( 2 9 ) . In some of these 
conditions the basal levels of hGH are elevated (not however in 
hypothyroidism and mental depression). Both the elevated basal 
levels, as well as the antinomous increase of hGH in response to 
factors such as TRH, were ascribed to a dysfunction of central 
nervous system inhibitory mechanisms of growth hormone secretion. 
Overproduction of serotonin, the occurrence of false neurotrans-
mitters and even more speculative explanations were alluded to. 
All these explanations tacitly assume, that in the absence of 
effective inhibitory control of hGH release, TRH (and LRH) as 
such increases the release of this hormone. In this context it is 
interesting to know that in the conditions in which TRH increases 
the release of growth hormone, glucose loading paradoxically in-
creases plasma growth hormone levels, whereas in normal physiology 
hyperglycaemia leads to complete suppression of growth hormone 
release. Such anomalous response of GH to glucose was found in: 
protein calorie malnutrition ( 3 0 ) , anorexia nervosa ( 3 1 ) , predia-
betes mellitus ( 3 2 ) , renal failure ( 3 3 ) , chronic liver disease ( 3 4 ) , 
Turner's syndrome ( 3 5 ) , acute intermittent porphyria (36) and in 
neonatal infants ( 3 7 ) . Our observation, that in the physiology of 
normal puberty, glucose loading transiently evokes hGH release, is 
also of interest (38). In acromegaly, such paradoxical increase of 
hGH in response to glucose loading is well-known in about 30% of 
the patients ( 3 9 ) . 
A third phenomenon of paradoxical hGH responses comes from 
studies on the role of dopamine. In healthy men, administration of 
L-dopa and other dopaminergic drugs (bromocryptine) leads to relea-
se of hGH, whereas in acromegaly such administration paradoxically 
suppresses hGH secretion frequently. In addition, it has been 
shown that inhibition of hGH by dopaminergic drugs occurs in 
those acromegalics whose hGH levels are stimulated by TRH ( 4 0 ) . 
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These findings led several authors to the hypothesis that there 
are two groups of patients with acromegaly: one in which hGH le­
vels can be stimulated by TRH and inhibited by dopaminergic agents 
and a second group in which neither TRH nor dopaminergic drugs 
have any effect on hGH secretion. There are several hypothetical 
models to explain the existence of these two groups: 
i. Acromegaly is a primary pi tui tary disease, originating from 
the development of an autonomously functioning hGH producing ade­
noma. Some of these adenomas have receptors for TRH and dopaminer­
gic agents; in other adenomas these receptors are lacking (41, 4 2 ) . 
The finding, that surgically removed adenomas in vitro reacted 
to TRH and bromocryptine, similarly as they did in vivo before 
operation, supports this hypothesis (43, 4 4 ) . In addition, it is 
strengthened by the demonstration that hGH secretion normalizes 
and that paradoxical responses of hGH disappear after the selective 
removal of such adenoma (45). The recent observation of a TRH sti­
mulatory effect on hGH release in a patient with acromegaly and 
pituitary hyperplasia due to ectopic GHRH secretion, however 
argues against this hypothesis ( 4 6 ) . 
ii.Acromegaly is a primary hypothalami с disorder, leading to 
hyperplasia of the hGH producing cells of the hypophysis. The pri­
mary hypothalamic disorder might be absolute overproduction of 
GHRH or relative GHRH excess by SRIF deficiency. In this hypothe­
sis, a primary excess of GHRH leading to maximal hGH secretion, 
leads to secondary overproduction of hypothalamic SRIF (47, 4 8 ) . 
Thereby, maximal, though insufficient, inhibitory control is 
present. In this framework of maximal stimulation and maximal in­
hibition, there is no place neither for further stimulation, nor 
for further inhibition. These patients therefore will show a 
minimum of modulation of hGH secretion by any regulatory peptide. 
In case of hyperplasia of the somatotrophs due to relative over­
stimulation by GHRH, due to primary SRIF deficiency, the turn off 
of hGH secretion by exogenous SRIF and possibly so by dopaminergic 
drugs should be essentially normal. 
The possibility remains, that primary hypothalamic derangement 
leading to growth hormone release, on the long term might lead to 
the formation of an autonomously functioning growth hormone pro­
ducing adenoma. 
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In the study reported in chapter II, we investigated whether the 
administration of SRIF in increasing doses might provide evidence 
for the existence of so called SRIF "responders" and "non respon-
ders". These patients were further characterized by their respon-
ses to TRH, LRH and Bromocryptine (the oldest dopaminergic drug 
used for this purpose). This study resulted in the delineation of 
two groups of acromegalics, on the base of the response to SRIF, 
and it could be concluded that: 
i. SRIF responders regularly responded with hGH release to 
LRH whereas the non-responders never showed such anomalous LRH 
response. 
i i .non-responsiveness to SRIF does not preclude release of hGH 
by exogenous TRH neither suppression of hGH levels by bromocryptine. 
CUSHING's DISEASE 
Considering that up to 80% of patients with overproduction of 
hGH may show paradoxical increments of hGH in response to TRH and 
- though to a lower degree - to LRH we wondered whether such 
antinomous responses would also occur in patients with overpro-
duction of ACTH, notably in Cushing's disease. In 1976, we started 
this study and a preliminary report of these data is presented in 
chapter III. Paradoxical responsiveness of Cortisol in response to 
TRH and also to LRH occurred in 3 out of 6 patients with Cushing's 
disease. In one of these patients, ACTH levels were measured in 
addition and a paradoxical increase preceding the increment of 
Cortisol levels was found (not reported in chapter III). Indepen-
dently, Krieger and Luria (49) in 1977 reported increments of ACTH 
levels, followed by an increase of Cortisol levels in response to 
TRH administration in each of 6 patients with Cushing's disease, 
and of ACTH levels in 4 patients with Nelson's syndrome. Earlier 
Connell et al (50) reported that patients with Cushing's disease 
did not show any effect of ACTH levels in response to TRH adminis-
tration. Matsukura et al (51) did not find such responsiveness 
after TRH administration, but did find a paradoxical increment of 
ACTH and Cortisol in 1 patient after LRH administration in vivo, 
and of ACTH levels in vitro, using surgically removed pituitary 
tissue. 
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Whereas anomalous hGH responses to releasing hormones in a 
number of varying pathological conditions have amply been reported 
and discussed in the preceding paragraph (page 4 ) , such antinomous 
responses of the hypophyseal-adrenocortical axis in conditions 
other than Cushing's disease have not been reported so far. 
In 1978, we studied a 32 year old woman with oligomenorrhea 
and proven infertility during at least 8 years.Her pituitary func­
tion was tested by a number of procedures, among which a TRH-test. 
To our surprise, despite clinical and biochemical absence of signs 
of Cushing's disease, administration of the releasing hormone 
caused a dramatic increase of plasma Cortisol levels. Shortly 
thereafter, totally unexpected, it appeared that at the time of 
the test this woman was pregnant with an amenorrhea duration of 
10 weeks. This observation prompted us to study the response of 
ACTH and Cortisol levels to TRH administration in 6 additional 
pregnant women. The results of this study are presented in chapter 
IV. 
It is well-known, that in pregnancy the levels of ACTH and of 
free plasma Cortisol increase to supranormal values (52, 5 3 ) . More­
over, the suppressibi1 ity of the free plasma Cortisol levels by 
dexamethasone is diminished ( 5 3 ) . These observations point to an 
alteration of the hypothalamo-pituitary-adrenal axis in pregnancy, 
mimicking the defect in the regulation of ACTH in pituitary depen­
dent Cushing's disease. 
In animal physiology, a stimulatory effect of TRH on the relea­
se of ACTH and of ACTH-derived peptides such as α-melanocyte sti­
mulating hormone ( a - M S H ) , was recently described in rats ( 5 4 ) , 
frogs ( 5 5 ) , dogs (56) and rabbits (H. Goverde et al, unpublished 
observations). These species all have a well developed intermediate 
lobe in their pituitary. Gershengorn et al ( 5 7 ) , using in vitro 
monolayer cultures from the anterior lobe of male Sprague-Dawley 
rats, did not find TRH-induced ACTH release. The presence of a-MSH 
is generally considered as a marker of a functioning intermediate 
lobe, therefore one might wonder whether TRH mediated ACTH release 
takes place only in the intermediate lobe. 
In healthy adult men - as in a number of other species e.g. all 
bird species, elephants, manatees, whales and armadillos - the 
intermediate lobe is anatomically absent ( 5 8 ) , whereas in the human 
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Figure 1: Structure formula of bovine proopiolipomelanocortiη ( 7 1 ) . 
Abbrevi ations: Products processed from 
proopiolipomelanocortiη : 
Ala Alanine 
Arg Arginine 
Asn Asparagine 
Asp Aspartate 
Cys Cysteine 
Gin Glutamine 
Glu Glutamate 
Gly Glycine 
His Histidine 
Ile Isoleuci ne 
Leu Leucine 
Met Methionine 
Phe Phenylalanine 
Pro Proline 
Ser Serine 
Thr Threonine 
Trp Tryptophan 
Tyr Tyrosine 
Val Valine 
- 131 -
- 56 -
+ 1 • 
+ 1 -
14 -
42 • 
42 -
102 -
• - 1 
- 44 
13 
39 
39 
• 132 
89 
- 132 
pro-Y-MSH 
γ-MSH 
ct-MSH 
ACTH 
CLIP 
ß-1i po trop i η 
γ-1ipotropin 
ß-endorphi η 
102 106 m e t - e n k e p h a l i η? 
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Het Pro A r g Leu C y s Ser 5er Arg Ser Gly A l a Leu Leu Ltu Ala Leu Leu Leu Gin Ala 
•131 
- 1 2 0 
Ser Glu T h r T h r Leu A s p Gin Cys Gin Ser Ser Glu Leu Cys Trp Gly Arg Val Glu Met 
•100 
Leu Leu A l a C y s Ile A r g A l a Cys L y s Pro A s p Leu Ser Ala Glu T h r P r o Val Phe Pro 
-80 
Arg P h e H i s G l y Met Val Туг Lys Arg Pro A s n G l u T h r L e u Pro G i n G l u A s p Gly A s n 
-60 
Asp Arg Phe Gly A r g A r g Asn Gly S e r Ser Ser Ser Gly гі Gly Gly A l a Ala Gin Lvs 
-40 
Gly T h r Glu A l a A s p A s p Gly Arg Pro G l y Pro G l y H u Gly Val Ala Val Glu Glu Glu 
-20 
Arg Glu A s p Lys Arg S e r Т у г Ser Met G l u His Phe Arg T r p Gly Lys Pro Val Gly Lys 
•1 1 
Pro Phe Ala G i n A l a S e r Glu A s p Glu Ala G l y A s n Pro Т у г Val L y s Val Pro Arg A r g 
20 
he L y s A r g G l u L e u A l a Gly A l a P r o P r o G l u Pro Ala Arg A s p Pro G l u Ala A l a 
I 
40 
Ala A l a Glu A l a G l u Ala Glu A l a Val Leu G l y T y r Glu Leu Glu Ala A r g Ala Ala Ala 
Lys Lys A s p S e r G l y Pro Tyr Lys Met Glu H i s P h e Arg T r p Gly Ser Pro Pro Lys A s p 
Lys Phe Leu Thr Val Leu Pro T h r Gin Ser L y s Glu Ser T h r Met Phe Gly G l y T y r Arg 
Ile Ile Lys Asn Ala His Lys Lys Gly Gin 
132 
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foetus a functioning intermediate lobe is present (59, 6 0 ) . In 
1978, Clark (61) demonstrated the presence of circulating a-MSH 
in pregnant women. Moreover, immunohistochemistry of pituitary 
tissue of a pregnant woman - who died from miliary tuberculosis -
demonstrated the presence of considerable amounts of a-MSH at the 
site of the intermediate lobe (62). Therefore we assumed, that in 
pregnant women a developing pars intermedia releases ACTH in res­
ponse to TRH. 
Cushing's disease, originating from the pars intermedia was 
reported in horses (63) and dogs (64). In human Cushing's disease, 
Lamberts (65, 66) suggested an intermediate origin of this disease, 
on the strength of the presence of neurosecretory fibers and gra­
nules, in the surgically removed pituitary tissue of several of 
his patients. As early as 1933, Harvey Cushing (67) also suspected 
this possibility. This finding is further substantiated by the 
demonstration of the presence of a-MSH in surgically removed pitui­
tary tumors of patients with Cushing's disease (68). Furthermore 
release of a-MSH by such a tumor was proven in vitro by Shibashaki 
(69). 
Differences are found in the regulation of ACTH release from 
the pars intermedia and the pars anterior of the pituitary. In 
both hypophyseal compartments, ACTH synthesis is the result of an 
enzymatic cleavage of a precursor molecule named proopiolipo-
melanocortin (POLMC). In addition this polypeptide consisting of 
263 amino-acids is the source of a number of ACTH related peptides 
including melanocyte stimulating hormones (a-MSH, γ - M S H ) , lipotro-
pins, endorphins and enkephalins (fig. 1) (70, 7 1 ) . The present 
knowledge of the biochemical pathways in the pars anterior and the 
pars intermedia is illustrated in fig. 2. The main products of the 
pars anterior are ACTH, ß-lipotropin and 0-endorphin, whereas the 
pars intermedia processes ACTH further to a-MSH and corticotropin 
like intermediate peptide (CLIP) (72). 
There are some differences in the physiological control of hor-
mone release between both lobes: the anterior cells are stimulated 
to release their hormones mainly by blood borne CRH and are inhi-
bited by glucocorticoids. By contrast, the hormone release of the 
intermediate lobe is under excitatory and inhibitory (dopaminergic) 
neural control, whereas its secretion is not affected by CRH or 
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anterior 
lobe 
: 
'intermediate 
lobe 
proopiolipomelanocortin 
1 — II 
л 
biosynthetic intermediate ß-lipotropin 1 ! • • • + Ι Г: ""·":: "1 A /\ 
proY-MSH ACTH ylipotropin P-endorphin 
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a-MSH CLIP ? 
Fig. 2. Processing of proopiolipomelanocortin in the pars anterior 
of the pituitary (upper panel). In the pars intermedia the pro­
cessing of proopiomelanocortin is identical, but ACTH and γ-lipo-
tropin (and possibly also ß-endorphin) are processed further to 
smaller products (lower pane l ) . 
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glucocorticoids (70). 
As mentioned above, Lamberts et al suggested an intermediate 
origin in a subgroup of patients with this disorder (66). These 
authors claimed that such intermediate lobe Cushing's patients, 
differed from those with anterior lobe pathology by a number of 
characteristics: A: the intermediate lobe patients were less 
sensitive to suppression of Cortisol levels by dexamethasone; 
B: their basal prolactin levels were higher and C: they responded 
to bromocryptine administration with a more pronounced decrease 
i η corti sol 1evels. 
From our own observations on ACTH and Cortisol responsiveness 
to TRH and/or LHRH in patients with Cushing's disease and from the 
data mentioned above on ACTH/MSH responsiveness to TRH in animals 
with proven intermediate lobe activity as well as on the strength 
of data on ACTH/cortisol responsiveness in pregnant women, we 
considered the possibility that such responsiveness might be the 
expression of intermediate lobe activity. To verify this hypothesis, 
we investigated whether ACTH and Cortisol dynamics and basal pro­
lactin levels differed between a group of TRH/LRH responsive and a 
group of non-responsive patients with Cushing's disease. The re­
sults are presented in chapter V. They do not allow firm statements 
on the validity of our hypothesis. 
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CHAPTER II 
SOMATOSTATIN SENSITIVITY AND GROWTH 
HORMONE RESPONSES TO RELEASING 
HORMONES AND BROMOCRYPT INE IN ACROMEGALY 
G.F.F.M. Pieters 
J.E. Romeij η 
A.G.H. Smals 
P.W.C. Kloppenborg 
ABSTRACT 
Infusion of increasing doses of somatostatin (SRIF) (respec­
tively 60, 120, and 300 ug/hour for 1 h) disclosed the presence 
of two groups of acromegalics. In group I (n = 8 patients), the 
elevated serum hGH levels (mean basal value 25 + 4 ng/nil (+ SEM)) 
decreased to normal values (hGH < 7.5 ng/ml ) , whereas in group II 
(n = 12) serum hGH levels (mean basal value 55 + 13 ng/ml; Ρ < 
0.01 vs group I) remained elevated (36 + 18 ng/ml during infusion 
of 300 ug SRIF). At each dose level of SRIF, the mean percentage 
decrease in group I was significantly greater than in group II 
(61 + 9% vs 19 + 4% at 60 yg/h, 64 + 7 vs 25 + 7% at 120 ug/h, and 
83 + 3 vs 35 + 7% at 300 pg/h; Ρ < 0.01 at each dose level). 
Serum hGH levels showed a significant rebound above basal values 
after stopping SRIF infusion only in group I. The difference in 
SRIF sensitivity between the 2 groups was further substantiated 
by the much higher rate of decline of hGH in group I (t,/ ? 56 + 13 
min in group I vs 260 + 75 min in group II (P < 0.01)). LRH (100 
ug) elicited a distinct hGH increase only in the group of acrome­
galics with the higher SRIF sensitivity (5 out of 8 patients in 
group I against 0 out of 12 patients in group II; Ρ < 0.01). In 
contrast, the responsiveness to TRH was similar in both groups 
(6 out of 8 in group I against 9 out of 12 in group I I ) , and acute 
bromocryptine administration (5 mg orally) proved equally potent 
in lowering hGH levels in both groups (percentage decrease 66 + 
13% in group I vs 67 + 8% in group II; Ρ > 0.10 ) . 
We conclude the following: 1) The present data confirm the 
existence of two distinct subgroups of acromegalics characterized 
by differing sensitivities to SRIF. Endogenous SRIF deficiency in 
the more sensitive subgroup might account for this difference. 
2) LRH induced a marked hGH increase only in the SRIF normal izers, 
suggesting a tight connection between the action of these hypotha­
lamic factors. The absence of such linkage between TRH and SRIF 
responses points to different modes of action of TRH and LRH at 
the somatotroph; 3) SRIF responsiveness does not parallel the 
bromocryptine response in acromegaly. Therefore, long-acting hGH-
34 
specific SRIF analogs may play a pivotal role in future medical 
treatment of acromegaly unresponsive to bromocryptine 
INTRODUCTION 
In acromegaly modulation of human GH (hGH) levels by the hypo-
thalamic releasing hormones TRH, LRH, and somatostatin (SRIF) and 
the response to bromocryptine are highly variable ( 1 - 9 ) . Several 
hypotheses have been proposed to explain this variability. 
Some authors (10, 11) argue for the occurrence of two groups 
of acromegalics, one governed by autonomously functioning pituita-
ry adenomas and a second one primarily caused by hypothalamic de-
rangement. Other authors (11-14) state that the essential defect 
in acromegaly is always located in the hypothalamus and postulate 
GH-releasing hormone excess and defective secretion of SRIF as 
two mechanisms that can lead to overproduction of hGH. If this 
latter hypothesis were true, a different pattern of SRIF sensiti-
vity would be expected between the two groups of acromegalics. In 
the case of SRIF deficiency as the cause of hGH excess, administra-
tion of this tetradecapeptide would be expected to correct hGH 
overproduction completely; whereas in the case of GHRH excess in 
the presence of normal or enhanced endogenous SRIF, the response 
to exogenous SRIF should be less marked. Indeed, very recently 
Hanew et al (15) distinguished two groups of acromegalics on the 
strength of the response to SRIF. Only in the group with the higher 
SRIF responsiveness did these authors find hGH release after admi-
nistration of LRH, TRH, or arginine. In addition, this group showed 
normalization of hGH levels after bromcryptine. 
The present study confirms the existence of two groups of acro-
megalics with different dose-related sensitivity to SRIF. At varian-
ce with the findings of Hanew et al ( 1 5 ) , the groups did not differ 
in their hGH response either to TRH or to bromocryptine but did so, 
remarkably, in their hGH response to LRH. 
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Table 1. Individual hGH values in response to TRH, LRH, 
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29 
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mm 
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SUBJECTS AND METHODS 
Twenty patients with untreated active acromegaly (8 men, mean 
η л j. л Ί „.. range 31-70 yr, and 12 women, mean age 
studied. Informed consent was 
Basi e, 
Bromocryptine (5 mg Parlodel; Sandoz) was administered orally 
36 
SRIF, and bromocryptine in 20 patients with acromegaly 
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at 0800 h. Blood samples for hGH assay were taken before and every 
hour after bromocryptine loading until noon. 
All tests were performed with the patients fasting and at bed 
rest, on separate occasions with an interval of at least 2 days 
between the successive tests. Blood was sampled via an indwelling 
i.v. cánula kept open with minute amounts of a diluted (10%) solu-
tion of heparin. 
Plasma hGH levels were measured by RIA as reported earlier (16). 
Plasma testosterone ( 1 7 ) , serum "U and T 4 ( 1 8 ) , and serum PRL (19) 
were measured by specific RIAs as reported before. Glucose toleran-
ce was evaluated by measuring blood glucose 2h after an oral gluco-
se load of 100 g. Sellar volume was determined according to the 
method of Di Ghiro (20). 
Statistical analysis was performed using Wilcoxon's two sample 
test to assess the differences between two groups ( P ) , Wilcoxon's 
γ 
paired rank test to assess differences within the same group (P ) , 
Spearman's rank correlation test ( P x x ) , Friedmann's non oarametric 
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analysis of variance to test the significance of hGH decreases in 
response to SRIF and bromocryptine ( P x x x )
>
 Fisher's χ test to test 
differences in frequency between two groups ( p x x x ) , and Bonferoni 
's method to make simultaneous influences about multiple mutually 
dependent variables (21). The mean values + SEM are given. 
RESULTS 
Plasma hGH response to SRIF (Table 1, Fig. 1 ) . 
The acromegalics could be divided in two groups according to 
their response pattern to increasing doses of SRIF: in 8 patients 
(3 men, 5 women) serum hGH levels normalized (< 7.5 ng/ml; group 
I ) , whereas in the remaining 12 patients (5 men, 7 women) serum 
hGH levels remained elevated even during the highest dose of SRIF 
(group I I ) . The mean basal hGH levels calculated from the values 
at time 0 during each of the tests in which blood sampling star­
ted at -30 in group I were significantly lower than in group II 
(25 + 4 ng/ml vs 55 + 13 ng/ml; Ρ < 0 . 0 1 ) . 
Although serum hGH levels during SRIF infusion normalized only 
in group I, in group II SRIF administration also elicited a dose-
related decrease in plasma hGH levels ( p x x x < 0.001). However,both 
curves ran a dissociated course (Bonferoni's multiple comparison 
test (P < 0.05 ) ) , i.e. at each dose level of SRIF the relative 
hGH decrease in group II was significantly less than in group I: 
19 + 4 vs 61 + 9% at 60 yg/h, 25 + 7 vs 64 + 7% at 120 yg/h, and 
35 + 7 vs 83 + 3% at 300 yg/h (P < 0 . 0 1 ) . In group I normalization 
of the elevated hGH levels was achieved at the lowest dose of SRIF 
in 2 of 8 patients, at 120 yg/h in 6 of 8, and at 300 yg/h in all 
patients. The rate of GH decline, expressed as half time value, 
was 56 + 13 min during the administration of 60 yg SRIF in group 
I. The calculated t,,^ during the same dosage of SRIF in group II 
was 260 + 75 min (Ρ < 0.01 vs group I) ( F i g . 2 ) . 
After stopping SRIF infusion, in group I hGH showed a rebound 
to levels (39.5 + 2.7 ng/ml) exceeding the baseline values ( P x = 
0 . 0 2 ) , whereas in group II hGH returned to levels not statistical­
ly different from pretreatment values (69 + 16 ng/ml; P x > 0 . 1 0 ) . 
Both subgroups of acromegalics did not differ from each other 
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Fig. 1. Mean percentage changes (+ SEM) of serum hGH levels (AhGH) 
before, during, and after infusion of increasing doses of SRIF (Se-
rono; 60, 120, and 300 yg/h successively, each for 1 h ) . · * . Statis­
tically significant differences in mean percentage changes between 
the two groups at the different time intervals (P<0.01).o o, 
SRIF nonnormal izers (n = 1 2 ) ; · ·, SRIF normalizers (n = 8 ) . 
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Fig. 2. The effect of SRIF infusion at a rate of 60 yg/h on the 
mean (+ SEM) percentage change in hGH levels (AhGH) in patients 
with acromegaly.о OjSRIF nonnormal i zers (n = 12);· ».SRIF 
normalizers (n=8) during the first hour (*, Ρ < 0.05;J ,P < 0.01), 
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in age, sex, duration of disease, thyroidal or gonadal status, or 
basal PRL levels but did differ in their response to glucose 
loading; glucose tolerance was significantly more impaired in group 
II than in group I (P < 0.02; Table 2 ) . 
Effect of TRH and LRH on olasFia hGH in relation to SRIF resoonsi-
veness (Tabi e 1, Fig. 3 ) . 
In group I, 5 of 8 patients showed a paradoxical response of 
hGH to LRH administration (i.e., values exceeding 50% (range 95 -
> 212%) above baseline in at least 2 samples and within 30 m i n ) , 
whereas none of the 12 acromegalics in group II showed such res­
ponse. The number of LRH responders differed significantly between 
the two groups ( P x x x x < 0.01). 
Six of the 8 patients whose hGH normalized during SRIF infusion 
demonstrated a paradoxical hGH increase (as defined above for LRH, 
range 57 - >585%) after TRH. Four patients showed this response 
with both releasing hormones. In nine of 12 patients in group II 
hGH levels also increased more than 50% (range >55 - 380%) after 
TRH loading ( P x x x x > o.l vs group I ) . 
Dissociation between the hGH response to SRIF and acute bromocryp-
tine administration (Fig. 4 ) . 
In both groups I and II hGH levels decreased significantly 
( p x x x < 0.0005) after acute bromcryptine administration, the mean 
percentage decrease being similar in both groups (66 + 13 vs 67 + 
8%; Ρ > 0.10) . No significant correlation was found between the 
percentage decreases of hGH during SRIF or bromocryptine adminis­
tration (r = 0.11; P x x > 0.10). In group I, half of the acromegal­
ics showed normalization of the elevated hGH levels after bromo-
cryptine administration, and in group II, 5 out of 12 (P > 
0.10). In the TRH responder group, serum hGH levels normalized 
after bromocryptine administration in 8 of 15 patients as compared 
to 1 of 5 subjects in the TRH nonresponder group ( p x x x x > 0.10). 
Two of 5 patients in the LHRH responder group and 7 of 15 in the 
LHRH nonresponder group showed normalization of the elevated hGH 
levels ( P x x x x > 0.10). 
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Fig. 3. Individual percentage changes in serum hGH levels to LRH 
(100 \ig Relefact (Hoechst) iv; Щ ) or TRH (200 vg TRF (Roche) iv; 
|) in SRIF-normalizing (n = 8) and nonnormal i zing (n=12) acromega­
lics. Ragged edge at the top of the vertical bar indicates that 
the hGH concentration exceeded the upper limit of the assay, and 
insufficient serum remained for further dilutions. Note that LRH 
evoked a significant increase of hGH, exceeding 50% only in the 
group of SRIF normalizers. 
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Fig. 4. Mean percentage changes of serum hGH levels (AhGH) after 
bromocryptine administration (5 mg Parlodel (Sandoz)) in two 
groups of acromegalics; SRIF normalizers ( · — · ; n=8) and nonnor-
malizers (o о ; n=12). 
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Table 2. 
Clinical and biochemical data in 20 patients with acromegaly 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
θ 
9 
IO 
11 
12 
1 I 
14 
15 
16 
17 
18 
19 
20 
Age (yr) 
34 
47 
65 
39 
5b 
40 
61 
52 
56 
19 
35 
37 
70 
55 
62 
31 
57 
46 
32 
26 
Sex 
M 
M 
F 
F 
F 
F 
F 
M 
F 
F 
M 
F 
M 
F 
F 
M 
F 
M 
M 
F 
Duration of 
disease ( г) 
5 
>5 
>15 
>5 
3 
3 
>10 
e 
>20 
2 
3 
5 
>10 
>20 
10 
8 
>10 
6 
5 
3 
Sellar volume 
(mm1)" 
6160 
1824 
2565 
2052 
1365 
2933 
2660 
1183 
4β40 
2380 
2660 
1792 
2021 
1547 
2907 
1950 
2772 
1890 
2904 
2805 
Glucose 2 h 
after 100 g 
glucose 
(mmol/liter) 
54 
44 
54 
54 
90 
55 
60 
56 
20 0 
72 
10 0 
64 
70 
9 3 
8 3 
6 1 
195 
85 
90 
59 
Τ, (ng/ 
100 ml)" 
122 
131 
144 
184 
178 
146 
144 
112 
74 
1 № 
169 
123 
201 
159 
150 
m 
I5J 
129 
118 
193 
T. (μ6/100 
mil 
8 8 
89 
92 
79 
U J 
73 
10 3 
8 6 
4 0 
65 
79 
86 
11 9 
10 0 
78 
70 
8 3 
96 
86 
58 
Menses 
Menopause 
Normal 
Menopause 
Normal 
Menopause 
Menopause 
Amenorrhea 
Amenorrhea 
Menopause 
Menopause 
Menopause 
Amenorrhea 
Tesloster 
one 
(ng/100 
ml)* 
365 
157 
28J 
371 
210 
480 
421 
530 
PRL 
(pg/mlr 
7 
9 
5 
6 
6 
34 
4 
14 
2 
6 
22 
21 
2 
12 
24 
90 
31 
2 
22 
20 
Mean ± so 49 2 ± 1 0 4 > 6 75 ± 3 8 2718 ± 1512 5 8 ± 1 1 145 ± 25 9 J ± l f 
patients 1-8 
Mean ± SD 43 8 ± 1 5 3 >8 5 ± 5 8 2539 ± 832 9 76 ± 4 6 146 ± 12 80 ± 2 0 
patients 9-20 
335 ± 37 10 6 ± 9 3 
385 ± 11 ¿ 1 5 + 230 
" Normal <1100 mm1 
'Normal 90-190 mg/100 ml 
' Normal, 5 0-11 5 /ιί/100 ml 
^ Normal male >300 ng/100 ml 
' Normal female, <20 pg/ml, normal male <15 pg/ml 
DISCUSSION 
Administration of increasing doses of SRIF disclosed the pre­
sence of two groups of acromegalics: in one group the elevated 
serum hGH levels decreased to normal values, whereas in the second 
group hGH levels decreased but still remained elevated. At each 
dose level of SRIF the mean percentage decrease of serum hGH was 
greater in group I than in group II. This difference in SRIF sen­
sitivity is emphasized by a significant difference in the rate 
of decline of hGH between both groups. Only in group I did hGH 
show a significant rebound after SRIF infusion to levels exceeding 
the baseline values. This difference in rebound between the two 
groups may also be considered to be an expression of a difference 
in sensitivity to exogenous SRIF. 
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Together, these data suggest that the subgroup of acromegalics 
with higher sensitivity to exogenous SRIF might be deficient in 
endogenous SRIF. The finding of lower basal hGH levels in group I 
also fits this concept: deficiency of a natural inhibitor of hGH 
production could theoretically lead to a smaller excess than pri-
mary overproduction of hGH due either to surplus GH-releasing hor-
mone or to an autonomously functioning pituitary adenoma. Another 
explanation might be that in mild acromegaly with lower hGH levels, 
the somatotrophs are more sensitive to SRIF than in severe acrome-
galy with higher hGH levels, possibly leading to higher endogenous 
SRIF activity. Reflecting the higher hGH levels, glucose tolerance 
was significantly more impaired in group II than in group I. Dif-
ferences in duration of disease cannot account for the differen-
ces in SRIF sensitivity found. 
The presence of two distinct subgroups in our patients confirms 
the finding of Hanew et al (15) of two groups of acromegalics ha-
ving differing sensitivities to SRIF. In contrast to the present 
data, however, they observed no significant difference in basal 
hGH levels between their patient groups (33 vs 42 ng/ml) , despite 
a finding of lower basal glucose levels in the group having the 
greater sensitivity to SRIF. 
We have calculated similar differences in SRIF sensitivity 
from the data of Opizzi et al ( 2 2 ) . In accordance with our data, 
basal serum hGH levels were lower in those acromegalics who show-
ed normalization of their hGH levels during SRIF administration 
than in those who did not. 
The two groups of acromegalics in the present study differed 
in still another way: only in the group of acromegalics with the 
higher SRIF sensitivity was a paradoxical rise in hGH levels 
elicited by LRH, whereas the hGH response to TRH loading did not 
differ significantly between the 2 groups. This finding clearly 
indicates that in a significant proportion of acromegalics grea-
ter SRIF sensitivity is linked to a paradoxical increase of hGH 
in response to LRH, although not to TRH. A similar linkage was 
reported earlier for the responses to TRH and bromocryptine ( 2 3 ) . 
Our data are somewhat at variance with those of Hanew et al ( 1 5 ) , 
who demonstrated that acromegalics who exhibit a large hGH in-
crease to at least one of the stimuli (LRH, TRH, and arginine) 
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show the highest responsiveness to SRIF. Our data point only to 
a tight connection between the responses to SRIF and LRH. 
An inverse relationship between TRH- and LRH-induced hGH 
increases can be deduced from the figures of Hanew et al (15).In 
their SRIF-responsive group the higher LRH-induced hGH increments 
were found in the patients with the lower TRH responsiveness and 
vice versa. Although this inverse relationship was expressed less 
in our patients, this finding suggests that the actions of LRH 
and TRH on the pituitary somatotrophs are modulated by different 
mechanisms. Ishibashi et al (24, 25) observed that only the LRH-
induced hGH increment, and not that of TRH, could be abolished by 
concomitant bromocryptine administration. We have confirmed this 
finding (Pieters, G.F.F.M., J.E. Romeijn, A.G.H. Smals, and P.W.C. 
Kloppenborg, unpublished d a t a ) . These data also point to a diffe­
rent mechanism of action of the two releasing hormones on the so­
matotrophs of acromegalics. 
The close relationship between the responses of SRIF and LRH 
was not found between the responses to bromocryptine and LRH. Bro-
mocryptine proved equally potent in lowering hGH levels in both 
the LRH responders and the LRH nonresponders. Furthermore, no 
correlation was found between the SRIF and the bromocryptine 
responses. This finding is at variance with data of some investi­
gators (13, 22, 26, 27) who have found a close relation between 
SRIF and bromocryptine sensitivity. Other authors, like us, have 
denied such a correlation ( 2 8 ) . 
The fact that some acromegalic patients who do not respond 
adequately to bromocryptine do normalize their hGH levels during 
SRIF administration indicates that in the future with the develop­
ment of hGH-specif i с, longer acting, SRIF analogs, more patients 
with acromegaly can be succesfully treated medically. 
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CHAPTER III 
PLASMA CORTISOL RESPONSE TO THYROTROPIN-RELEAS ING 
HORMONE AND LUTEINIZING HORMONE-RELEASING 
HORMONE IN CUSHING's DISEASE 
Gerlach F.F.M. Pieters 
Anthony G.H. Smals 
Theo J. Benraad 
Peter W.C. Kloppenborg 
ABSTRACT 
In 3 of 6 patients with pituitary-dependent Cushing's disease, 
a paradoxical increase of plasma Cortisol was observed both after 
LRH (Дтах 13.9 + 3.7 ug/100 ml; 113 + 52%) and TRH (Лтах 8.0 + 
2.9 yg/100 ml; 53 + 18%) administration, the maximum values being 
achieved 30 - 60 min after the iv bolus injection. In the remai­
ning 3 patients and in 15 control subjects, plasma Cortisol levels 
did not rise in response to either LRH or TRH administration but 
rather showed a slight to distinct decrease during the study period. 
The paradoxical Cortisol response in half of the patients with 
Cushing's disease may be the consequence of loss of specificity 
of the pituitary receptor or alteration in the hypothalamo-pitui-
tary pathways. 
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A paradoxical increase of plasma Cortisol and/or ACTH in res-
ponse to TRH recently has been reported by Krieger et al in pa-
tients with Cushing's disease or Nelson's syndrome (1, 2 ) , but the 
data have not been confirmed by others (3, 4 ) . Connell et al (3) 
and Matsukura et al (4) did not observe an increase of ACTH and/ 
or Cortisol after TRH administration in treated and untreated 
patients with Cushing's disease. The latter author, however, repor-
ted a paradoxical increase of ACTH and Cortisol after iv injection 
of LRH in one patient with Cushing's disease due to a pituitary 
adenoma ( 4 ) . In view of these contradictory data, it seemed worth-
while to study systematically the effect of both releasing hormones 
on adrenocortical function in patients with Cushing's disease. 
MATERIALS AND METHODS 
Six women with pituitary-dependent Cushing's disease (mean age 
+ SD, 39.3 + 13.4 yr) were given both 200 yg TRH (TRF, Roche) and 
100 pg LRH (LHRH, Hoechst) iv as a bolus injection on two separate 
occasions with an interval of at least 2 days. Fifteen healthy 
subjects (mean age + SD, 26.3 + 12.4 yr) received 200 pg TRH and 
15 other healthy controls (27.6 + 6.9 yr) received 100 \ig LRH. In-
formed consent was obtained from all patients and controls. All 
tests were performed with the patients and control subjects fasting 
and at bedrest. Blood samples for the Cortisol assay were collected 
at -30, 0, 10, 20, 30, 60 and 120 min after TRH or LRH administra-
tion,using an indwelling iv cánula kept open with minute amounts of 
a diluted (10%) solution of heparin. 
Plasma Cortisol levels were measured by a specific RIA.using an 
antibody raised against Cortisol-21-hemisuccinate coupled to bovine 
serum albumin, as described previously ( 5 ) . The intra-assay variation 
was 5%. All samples from the same subject were measured in the same 
assay. Statistical analysis was performed by using Student's paired 
t test. Unless otherwise stated, the means + SD are given. 
RESULTS 
The results are given in Fig. 1. All control subjects showed 
a gradual decrease of plasma Cortisol levels after administration 
of both releasing hormones; the maximum decreases were achieved 
120 min after TRH (40 + 19%) and 60 min after LRH (28 + 26%) admi-
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Fig. 1. Effect of LRH (100 ug iv) and TRH (200 ug iv) bolus injec­
tions on plasma Cortisol levels in 6 patients with Cushing's dis­
ease and 15 control subjects (shaded a r e a ) . Left panel. Patients 
who showed a paradoxical Cortisol response to both releasing hor­
mones; right panel, nonresponders. 
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nistration. In the LRH experiment, the decrease was already sta­
tistically significant 30 min after the bolus injection (P < 0.01) 
and was statistically significant in the TRH study after 60 min 
(Ρ < 0.01). Remarkably, after LRH administration the decrease was 
followed by a slight but not significant increase at 120 min. In 
three of the six patients with Cushing's disease, a paradoxical 
increase of plasma Cortisol was observed after LRH administration 
(Amax 13.9 + 3.7 yg/100 ml; 113 + 5 2 % ) ; the maximum values were 
achieved 60 min after the bolus injection. The Cortisol levels 
were still supranormal at 120 min. 
After TRH administration, the maximum increase in these three 
patients was' slightly lower (Amax 8.0 + 2.9 yg/100 ml; 53 + 1 8 % ) . 
Two of these three patients who showed a paradoxical Cortisol 
increase had roentgenological evidence of sellar enlargement. 
In the three remaining patients with Cushing's disease, plasma 
Cortisol levels did not rise after TRH or LRH administration but 
slightly decreased in the 2-h interval after the bolus injections. 
On both occasions, basal plasma Cortisol levels in these patients 
tended to be higher (20.1 + 3.2 ug/100 ml) than in the group of 
patients showing a paradoxical increase (13.7 + 1.6 yg/100 m l ) . 
DISCUSSION 
This study shows that in half of the patients with Cushing's 
disease in the present study a paradoxical increase of plasma 
Cortisol in response to both TRH and LRH was observed, suggesting 
loss of specificity of the pituitary receptor, with nonspecific 
polypeptide hormones leading to release of ACTH. 
In the other patients with Cushing's disease and in the control 
subjects, neither releasing hormone elicited a plasma Cortisol 
increase but rather showed a decrease, which in the control sub­
jects could be accounted for by the physiologically occurring 
diurnal variation of plasma Cortisol. A similar decrease of plasma 
Cortisol (25%) was reported by Anderson et al (6) in the 2-h inter­
val after TRH administration in normal men. The admittedly slight 
decrease of plasma Cortisol in the patients with Cushing's disease 
after releasing hormone administration could be ascribed to blun­
ting of the diurnal variation in this condition (7). 
A paradoxical increase of plasma Cortisol and ACTH by TRH 
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recently has been reported by Krieger et al (1) in six patients 
with untreated Cushing's disease; the mean maximum Cortisol incre­
ments (11.9 + 7.4 pg/100 ml) achieved after 45-90 min were of the 
same order of magnitude as those found in the present study. In 
contrast, Connell et al (3) and Matsukura (4) did not observe 
any effect of TRH on plasma ACTH or Cortisol levels in treated 
or untreated patients with Cushing's disease. The latter authors, 
however, reported a paradoxical increase of Cortisol and ACTH after 
administration of LRH in one patient. 
The present study indicates that nonspecific pituitary-
adrenocortical axis stimulation occurs not only after TRH but 
also after LRH administration in half of the patients with Cush­
ing's disease. Remarkably, of these three patients, two showed 
sellar enlargement. This loss of pituitary specificity of the 
receptor of the adenoma cells also has been reported in acromega­
lics, of whom 10-15% show paradoxical GH increases to both TRH 
and LRH (8-10). In these studies, no correlation was found between 
basal GH levels and their response to the non-specific stimulator, 
whereas in the present study, a paradoxical Cortisol increase 
tended to occur preferentially in patients with lower basal Cortisol 
1evels. 
The mechanism underlying the paradoxical Cortisol response in 
Cushing's disease is not known. An alteration of the cellular 
membrane receptors of the pituitary adenoma has been suggested by 
Faglia et al (8, 11) and recently, this hypothesis has been streng­
thened by Matsukura et al ( 4 ) , who demonstrated nonspecific stimu­
lation in vitro by TRH, LRH, and biogenic amines of adenylcyclase 
in isolated human GH- and ACTH-producing pituitary adenomas. 
Apart from alterations in cellular membrane receptor, another 
mechanism may be responsible for the anomalous Cortisol response 
to TRH or LRH in these patients. The paradoxical Cortisol increase 
in patients with Cushing's disease may be the consequence of ana­
tomical or functional disruption of hypothalamus-pituitary mono-
aminergic pathways ( 2 ) , stimulating neurotransmitter-induced ACTH 
release. Krieger et al (2) recently demonstrated that the circadian 
periodicity and TRH-induced anomalous ACTH response could be re­
versed by the administration of cyproheptadine, a serotoninergiс 
blocking agent. 
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CHAPTER IV 
PARADOXICAL RESPONSIVENESS OF ADRENOCORTICOTROPIN 
AND CORTISOL TO THYROTROPIN-RELEASING HORMONE 
(TRH) IN PREGNANT WOMEN. EVIDENCE FOR 
INTERMEDIATE LOBE ACTIVITY? 
G.F.F.M. Pieters 
A.G.H. Smals 
H.J.M. Goverde 
P.W.C. Kloppenborg 
ABSTRACT 
In 7 pregnant women, plasma immunoreactive ACTH and Cortisol 
rose paradoxically after intravenous administration of TRH but 
not after saline. This anomalous response to TRH is reminiscent 
of that in about one third of patients with Cushing's disease. 
These observations adduce inferential evidence to the concept 
that in pregnancy and in a subgroup of patients with Cushing's 
disease the intermediate lobe of the pituitary is the source of 
circulating immunoreactive and bioactive ACTH responding to TRH. 
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Recently Krieger and Luria (1) demonstrated that thyrotropin-
releasing hormone (TRH) can stimulate adrenocorticotropin (ACTH) 
and Cortisol release in some patients with Cushing's disease. We 
demonstrated that not only TRH but also luteinizing hormone-relea­
sing hormone (LRH) can stimulate ACTH and Cortisol release in such 
patients ( 2 ) . Oki et al extended this finding by showing increased 
in vitro release of ACTH, @ endorphin and γ MSH by cell suspensions 
of the pituitary tumor from a patient with Cushing's disease in 
response to both TRH and LHRH (3). Over the last years we have 
found such paradoxical ACTH and Cortisol release to TRH in 8 of 22 
consecutive patients with this disease (Pieters et al, in prepara­
tion). 
Recently Lamberts et al (4) reported the presence of neurose­
cretory fibers and granules in surgically removed pituitary tissue 
in one patient with Cushing's disease, who was 'TRH responder'. 
Very recently these authors reported their findings in 15 patients 
with Cushing's disease and demonstrated that б of them histologi­
cally had hyperplasia of the intermediate lobe of the pituitary, 
whereas the remaining 9 patients had an adenoma of the pars ante­
rior (5). As early as 1933 Harvey Gushing also suspected this pos­
sibility when he found basophilic cells infiltrating the posterior 
lobe from the pars intermedia of the pituitary gland in some of his 
patients ( 6 ) . Shibashaki et al (7) showed the in vitro secretion 
of pro-opio-melanocortin-derived peptides such as a-melanocyte-
stimulating hormone (a M S H ) , 3-lipotropin (β L P H ) , ß-endorphin and 
γ MSH in addition to ACTH by the pituitary tumor from a patient 
with Cushing's disease. Therefore, these authors also suggested 
that this tumor might have developed from cells migrating from the 
intermediate lobe of the pituitary. 
In preliminary reports (8, 9) TRH has been shown to be a 
potent releaser of ACTH in rats and α MSH in frogs, both of which 
species are known to have a well developed intermediate lobe. Ger-
shengorn (10) demonstrated that in vitro the cells of the pars 
anterior of the pituitary of rats do not show ACTH release in res­
ponse to TRH. From these data one might suspect that the pars inter­
media of rats is the source of ACTH release by TRH. 
In healthy adult males and females the intermediate lobe is 
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anatomically absent. During pregnancy, however, a typical inter­
mediate lobe peptide : a MSH is secreted by the pituitary (11). 
Recently Visser and Swaab adduced inferential evidence that the 
hypophysis of a pregnant woman contains an intermediate lobe by 
demonstrating immunohistochemically detectible α MSH (12). Further­
more in pregnancy free Cortisol (13-14) and ACTH (13) levels in 
plasma are elevated and show incomplete suppression to dexamethaso-
ne administration ( 1 3 ) . 
These data prompted us to measure the plasma ACTH and Cortisol 
responses to TRH in pregnant women. 
MATERIALS AND METHODS 
Seven healthy pregnant women with amenorrhea duration of 10 to 
23 weeks (mean + SD, 2 1 + 5 weeks, mean age + SD, 29.9 + 3.8 yr) 
volunteered for this study. Seven other healthy pregnant women with 
an amenorrhea duration of 10 to 25 weeks (mean 2 1 + 5 weeks, mean 
age 29.1 + 3.6 yr) served as control subjects. All subjects gave 
informed consent. 
The TRH test was performed at 9.00 a.m. with the subjects fas­
ting and at bed rest. Blood samples for assay of ACTH, Cortisol 
and TSH were taken at times 0, 10, 20, 30, 60 and 120 minutes via 
an indwelling intravenous cánula. The intravenous cánula (Abbo-
D 
cath -T, 16-G) was inserted 30 minutes before starting the test. 
D 
TRH (200 ug TRF , Roche) was given as a bolus injection after with-
drawal of the blood sample at t=0. In the control group the test 
was performed exactly in the same way but 2 ml saline was injected 
i.V. i nstead of TRH. 
ACTH, Cortisol and TSH were determined by specific radioimmuno-
assays as described previously (15, 1 6 ) . Statistical analysis was 
performed using Student's t-tests for paired (P denoted by P) and 
unpaired (P = P x ) values. The means + 1 SEM are given. 
RESULTS 
Data on the mean TSH, ACTH and Cortisol responses to TRH are 
depicted in figure 1. 
TSH 
The TSH response to TRH was significantly different from that 
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Figure. Mean TSH, immunoreactive ACTH and Cortisol responses to an 
intravenous bolus injection of TRH (t ·) or saline (o — o) in 2 
groups of 7 pregnant women. The vertical bars represent + SEM. The 
asterisks indicate statistical significance of differences between 
absolute TSH and Cortisol levels * Ρ < 0.05, * * Ρ < 0.01 Student's 
unpaired t test. « indicates significance (P < 0.05 Student's 
unpaired t test) of changes of plasma ACTH between 0 and 10 minutes 
in both groups (see text) 
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of the saline group at t = 10 min, P x < 0.01, t = 20 min, P x < 0.05 
and t = 30 min, P x < 0.05. 
ДСТН 
The response of ACTH to TRH was assessed in 5 pregnant women. 
Four of these 5 women showed an increase in their ACTH levels after 
TRH. One subject showed virtually no change in ACTH or plasma Cor­
tisol values following TRH. The mean ACTH level rose from a basal 
value of 40 + 18 pg/ml to 64 +.29 pg/ml at 10 minutes. Because of 
the small number of patients this rise was not significant. In the 
control group of 7 healthy pregnant women, however, ACTH levels 
virtually remained unchanged after saline injection. The increase 
in ACTH levels between times 0 and 10 minutes in the TRH group 
(17.4 + 10 pg/ml) was significantly higher than that in the saline 
group (-2 + 1 pg/ml, P x < 0.05). 
Cortisol 
The high basal levels of plasma Cortisol (23.1 + 4.0 ug/100 ml) 
are normal for pregnant women; these showed a further rise in res­
ponse to TRH (at 10 min, 29.3 + 3.8 pg/100 ml, Ρ < 0.005 vs 0'; at 
20 min, 30.0 + 3.6 мд/100 ml , Ρ < 0.005 vs 0'; at 30 min 32.2 + 4.0 
yg/lOO ml, Ρ < 0.05 vs 0 ' ) . Thereafter there was a gradual though 
significant decline (at 120 min, 22.1 + 1.8 ug/100 ml, Ρ < 0.05 vs 
3 0 ' ) . 
In the seven pregnant control subjects, plasma Cortisol levels 
decreased after saline to about 80% of the basal value (at time 
zero 20.6 + 1.8 yg/100 ml; at 10 min 19.9 + 1.8 yg/100 ml, Ρ > 0.10 
vs 0'; at 20 min 19.5 + 2.1 ug/100 ml, Ρ > 0.10 vs 0'; at 30 min 
17.7 + 2.1 ug/100 ml, Ρ > 0.05 vs 0'; at 60 min 15.9 + 2.1 мд/100 
ml , Ρ < 0.005 vs 0'; at 120 min 13.0 + 3.3 pg/100 ml, Ρ < 0.01 vs 
О
1)· 
Statistically significant differences in plasma Cortisol levels 
between the TRH and saline group were found at 10 min (P x < 0.05), 
20 min (P x < 0.05), and 30 min (P x < 0.01) after the injection. 
DISCUSSION 
The results demonstrate that in pregnant women ACTH and corti-
sol release is stimulated by TRH but not by saline. Such ACTH and 
Cortisol responses to TRH were not seen in healthy, nonpregnant 
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control subjects (2, 17) neither in women using conventional oral 
contraceptives (Pieters, unpublished). The origin of TRH-induced 
ACTH has yet to be settled. A placental origin of ACTH or ACTH-
like peptides and/or Cortisol must be excluded in order to presume 
pituitary TRH-induced ACTH release in pregnant women. In this con­
nection it should be noted that placental tissue contains several 
pituitary peptides including ACTH, β endorphin and α MSH (18, 19, 
2 0 ) . Recently, synthesis of these peptides by placental tissue was 
proven ( 2 1 ) . Furthermore, Liotta and Krieger (21) found processing 
of ACTH and ß-lipotropin to α MSH and β endorphin, respectively, 
by placental tissue, whereas post transiational processing could 
not be demonstrated in human pituitary tissue. Thus placental 
tissue processes 1 ipocorticotropins as does the intermediate lobe 
(22). On the other hand the finding of Csontos e.a. (23) that β 
endorphin and ACTH levels in the maternal venous plasma immediately 
after parturation were higher than those in the umbilical vein 
and artery plasma of the newborns argues for a pituitary origin of 
the increased levels of ACTH and β endorphin in pregnancy. Similar 
results were found for α MSH (11) and β lipotropin (24). 
The paradoxical responses of Cortisol and ACTH levels to TRH 
administration in pregnant women resembles the responses of these 
hormones found in approximately 35% of patients with Cushing's dis­
ease. 
Since responsiveness of ACTH/cortisol to TRH in animals seems 
to be confined to the intermediate lobe, and since it has been de­
monstrated (5) that about 40% of patients with Cushing's disease 
have hyperplasia of the intermediate lobe, it is relevant to inves­
tigate whether those Cushing-patients who show a paradoxical response 
of ACTH/cortisol to TRH have hyperplasia of the intermediate lobe, 
whereas non-responding patients are those with an autonomously func­
tioning (mi ero)adenoma of the pars anterior. 
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CHAPTER V 
ACTH AND CORTISOL RESPONSIVENESS TO TRH AND LRH 
DISCLOSES TWO SUBSETS OF PATIENTS WITH CUSHING'S DISEASE 
G.F.F.M. Pieters 
A.G.H. Smals 
H.J.M. Coverde 
G.J. Pesman 
E. Meyer 
P.W.C. Kloppenborg 
ABSTRACT 
In 23 consecutive patients with Cushing's disease and in 52 
control subjects the response of ACTH and Cortisol to TRH and to 
LRH was investigated. From the pattern of Cortisol levels after 
the administration of the releasing hormone in the controls a 
criterion for paradoxical responsiveness could be derived (Acorti-
sol > + 6.0 ug/100 m l ) . According to this criterion 9 patients 
with Cushing's disease showed a paradoxical responsiveness to one 
or both releasing hormones (3 to both TRH and LRH, 3 to TRH alone 
and 3 to LRH alone) (group I ) . In all patients tested paradoxical 
responses of Cortisol were preceded by paradoxical increments of 
ACTH. The remaining 15 patients showed no paradoxical increments 
of ACTH or Cortisol after TRH or LRH (group I I ) . ACTH levels in 
group I (89 + 28 pg/ml) were significantly lower than in group II 
(185 + 164 pg/ml, ρ < 0 . 0 2 ) . Nevertheless, in both groups a similar 
plasma Cortisol level was found, suggesting a relatively higher 
bioactivity of ACTH in group I. A second difference between both 
groups was a lower amplitude of Cortisol variability during the 
day in group I. Both groups did not differ in clinical data such 
as age, sex distribution, sellar volume and duration of disease or 
dexamethasone suppress!bi1 ity, bromocryptine sensitivity and basal 
prolactin levels. These latter findings do not favour an interme­
diate lobe origin of Cushing's disease in patients with paradoxi­
cal responses to TRH/LRH. 
To conclude, TRH/LRH responsiveness of ACTH/cortisol discloses 
two subsets of patients with Cushing's disease. 
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INTRODUCTION 
After the demonstration by Krieger et al (1) of an ACTH and/ 
or Cortisol stimulatory effect of TRH (thyrotropin releasing 
hormone) in patients with Cushing's disease and Nelson's syndrome, 
we showed that LRH (luteinizing hormone releasing hormone) can 
also evoke a similarly paradoxical response in some patients with 
Cushing's disease ( 2 ) . These findings were recently verified by 
other investigators in individual patients not only in vivo (3, 
4, 5, 6, 7, 8) but also in vitro with pituitary tissue of patients 
with Cushing's disease or Nelson's syndrome (3, 8 ) . This latter 
observation indicates a direct action of the releasing hormone on 
the ACTH producing pituitary adenoma cells in vitro. Together, 
these data are reminiscent of the paradoxical response of growth 
hormone to TRH and/or LRH in acromegaly (9, 10, 1 1 ) . 
In healthy men ACTH and/or Cortisol do not respond to TRH or 
LRH (2, 12, 1 3 ) . However in several animal species with a well 
developed pituitary intermediate lobe, TRH both in vivo as in 
vitro stimulates the release of ACTH (14, 15) and of aMSH ( 1 6 ) , 
a peptide specific for the intermediate lobe, and lacking in the 
pars anterior (17, 1 8 ) , whereas such stimulatory effect is absent 
in anterior lobe cells (19). In healthy adult men however, the 
hypophysis lacks a distinct pars intermedia (20, 21, 2 2 ) . In the 
fetus and in pregnant women the intermediate lobe is functionally 
active as has been demonstrated by its staining for aMSH and the 
presence of aMSH and CLIP (corticotropin like intermediate peptide) 
in venous plasma (23, 24, 2 5 ) . Our recent demonstration (26) that 
TRH can stimulate release of ACTH and Cortisol in pregnant women 
therefore suggests that in both man as well as in animal species, 
the presence of intermediate lobe remnants is a prerequisite for 
such a paradoxical TRH-induced ACTH response. 
Recently Olivier (27) demonstrated that in about one third of 
the patients with Cushing's disease the pituitary tumour contains 
considerable amounts of aMSH, a finding confirmed by Shibashaki 
et al (28). Furthermore, Lamberts et al (4, 29) adduced circumfe-
rential evidence that in some patients with Cushing's disease the 
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pituitary tumour might originate from the intermediate lobe. Simi­
lar findings were reported in dogs (30) and horses (31) with 
Cushi ng's di sease. 
It is well-known that the regulation of ACTH release from the 
intermediate lobe differs from that of the anterior lobe since the 
former is mainly regulated by dopaminergic and serotinergic 
nerve fibers and the latter by hypothalamic humoral factors (32). 
Therefore we wondered, whether patients with Cushing's disease 
paradoxically responding to a releasing hormone, differ in their 
ACTH and Cortisol secretion pattern from ' non-responders'. 
In this study, further evidence is produced of the existence 
of two subsets of patients with Cushing's disease based upon the 
responsiveness of ACTH/cortisol to TRH/LRH. The data however, do 
not favour an intermediate lobe origin of ACTH overproduction in 
Cushing-patients paradoxically responding to these releasing 
hormones. 
SUBJECTS AND METHODS 
Twenty-three consecutive patients with proven Cushing's disease 
(4 men, mean age + SD, 41 + 13 yr and 19 women, 38 + 10 yr) were 
studied. None of the patients was treated previously, except one 
patient (nr 6) with recurring Cushing's disease after unilateral 
adrenalectomy and pituitary irradiation 10 years earlier. 
Fifty-two healthy subjects without evidence of endocrine dis­
ease (11 men, age 38 + 15 yr and 41 women, 27 + 11 yr) served as 
controls for responsiveness of ACTH and Cortisol to TRH and LRH. 
Informed consent was obtained from all subjects. 
Plasma Cortisol rhythmicity in the Cushing patients was assess­
ed by repeated blood sampling at 08, 12, 16, 20, 24 and 04 hr. 
Dexamethasone suppressibi1 ity was studied with the 2 mg overnight 
test and the 2 day low (4 χ J mg daily) and high (4 χ 2 mg daily) 
dexamethasone test as described by Liddle ( 3 3 ) . 
D 
All 23 Cushing patients were given separately 200 ug TRH (TRF 
Roche, Basle, Switzerland) and 100 ug LRH (Relefact R, Hoechst, 
Frankfurt am Main, Germany) intravenously as a bolus injection on 
two different occasions with an interval of at least 2 days. In 2 
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patients multiple tests were performed. 
Thirty-eight healthy controls received TRH and 28 LRH, whereas 
14 subjects were given TRH as well as LRH on separate days. All 
tests started at 8 hr a.m. with the patients and control subjects 
fasting and at bedrest. Blood samples for hormone assay were col-
lected via an indwelling intravenous cánula kept open with minute 
amounts of a diluted (]Q%) solution of heparin, at times -30, 0, 
10, 20, 30, 60 and 120 minutes. 
The effect of bromocriptine on plasma Cortisol levels was exa-
mined by administering 5 mg of bromocriptine at 8.00 a.m. orally 
and blood sampling at 08, 09, 10, 11 and 12 hr in 16 patients with 
Cushi ng's di sease. 
Sellar volume was measured according to the method of Di Ghiro 
(34). 
Statistical analyses were performed using Wilcoxon's two 
sample test ( p ) , Wilcoxon's paired rank test ( p x ) . Spearman's rank 
correlation test ( p X X ) , Friedmann's non parametric analysis of va-
riance ( p X X X ) and Fisher's χ square test ( p x x x x ) . Unless otherwise 
stated the mean values + S.D. are given. 
Plasma Cortisol (35) and prolactin (36) levels were measured 
by specific radioimmunoassays as described before. 
Assay of ACTH 
Blood was collected in chilled polyethylene tubes containing 
50 μΐ heparin (250 U ) , and immediately centrifuged at 4 0 C . The 
plasma obtained was transferred to plastic tubes containing 1.000 
U trasylol, frozen and stored at -20 C. ACTH was extracted from 
the plasma (1-4 ml) using Vycor according to the method of Ratclif 
fe & Edwards (37). The entire extraction procedure was performed 
at about 4 0C. The dried extract was reconstituted in 250 μΐ stan­
dard diluent {0.9% Nacl , 0.5% BSA, pH 3.5 adjusted with 1 N HCl) 
and the mixture was centrifuged for 60 minutes at 30.000 g. The 
ACTH content of 100 yl of the supernatant was estimated in the as­
says. With each extraction procedure ACTH-free plasma (outdated 
blood bank p l a s m a ) , to which standard ACTH was added, was run for 
measuring the recovery. All samples were extracted in duplicate. 
ACTH immunoreactivity was measured by employing a midportion anti-
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body (Wellcome, RD 05) in a final dilution of 1 : 50.000. Highly 
125 purified human ACTH (Organon) was iodinated with I according 
to the 1actoperoxidase method of Mcllhinney & Schulster (38) 
obtaining specific activities of about 200 мСі/мд. Before use the 
tracer was purified on Sephadex G 50 using phosphate (0.02 M, 
0.25% BSA, pH 7.6) as the column buffer. Bound and free hormone 
were separated by a charcoal-pi asma mixture (39). 
Speci f i ci ty. Specificity of the antibody was tested by adding 
various ACTH-peptides in the radioimmunoassay. It appeared that 
the antibody used recognized especially the amino acid sequence 
17-24. The specificity was further tested in the assay by dilution 
of plasma sample extracts. All the samples studied paralleled the 
standard curve. 
Recovery. The recovery of radioactivity of the tracer added 
to different plasma samples amounted to 87.3 + 2.2%. The recove­
ries were independent of the plasma volume in the range 1-4 ml, 
as was tested by addition of tracer or (by addition of) standard 
ACTH to ACTH-free plasma. They were also independent of the amount 
of ACTH as was tested by addition of 25 to 4.000 pg to 4 ml ACTH-
free plasma. The mean recovery of standard ACTH - 2.000 pg/ml -
added to ACTH-free plasma was calculated on 28 occasions over a 
period of 1.5 year and proved to be 67.0 + 5.4%. In five different 
experiments, 100 pg standard was added to 12 different plasma 
samples of 4 ml obtained from different patients. The recoveries 
calculated did not differ from the recoveries of ACTH added to 
ACTH-free plasma. 
Sensi ti vi ty. With a recovery of 70% and a test volume of 100 
yl of a 250 yl extract of 4 ml plasma, the sensitivity in the 
radioimmunoassay could be calculated to be about 10 pg/ml. 
Reproduci bi1 i ty. Intraassay coefficients of variation for ACTH 
levels < 100 pg/ml and > 100 pg/ml respectively were 6.3% and 6.4%. 
The interassay coefficients for the same ACTH levels were 12.3% 
and 11.1%. To avoid interassay variation all samples from the TRH 
or LRH tests were measured in the same assay. 
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RESULTS 
CONTROL SUBJECTS (Fig. 1 ) . 
Response of Cortisol and ACTH to TRH. 
In 38 controls the response of plasma Cortisol to TRH was in-
vestigated. The mean plasma Cortisol levels declined significantly 
( p x x x < 0.0005) from 11.2 + 3.6 yg/100 ml at time 0 min to 10.9 + 
3.3 at 10 min, 10.9 + 3.3 at 20 min, 9.1 + 3.3 at 30 min, 7.3 + 
1.8 at 60 min and 6.2 + 2.5 wg/100 ml at 120 min. Nevertheless, it 
has to be stressed that seventeen of the control subjects showed 
a slight increase of plasma Cortisol during the first 30 min of 
the test of 1.8 + 1.5 ug/100 ml, range 0.4 to 4.0 pg/100 ml. 
The mean plasma ACTH levels measured in 21 of the 38 controls 
showed a significant decrease after TRH loading ( p x x x < 0.01) from 
34 + 14 pg/ml at time 0, to 35 + 16 pg/ml at 10 min, 28 + 10 at 20 
min, 27 + 12 at 30 min and 28 + 15 pg/ml at 60 min. The slight 
increase of plasma ACTH levels between 60 and 120 min from 28 + 15 
pg/ml to 32 + 12 pg/ml was not statistically significant (p x > 
0.10). 
Response of Cortisol and ACTH to LRH. 
In 28 control subjects the response of plasma Cortisol to LRH 
was investigated. The mean plasma Cortisol levels in these subjects 
significantly fell from 11.3 + 3.3 yg/100 ml at time 0 min to 9.8 
+ 3.6 at 10 min, 9.4 + 2.9 at 20 min, 7.3 + 3 at 30 min, and 7.6 
+ 2.5 ug/100 ml at 60 min ( p X X X < 0.0005). Remarkably, between 60 
and 120 min after LRH loading, plasma Cortisol levels significant-
ly increased to 10.2 + 6.2 yg/100 ml (p x < 0.02). 
Fourteen of the 28 control subjects revealed a slight increase 
of plasma Cortisol, ranging from 0.4 to 3.3 ug/100 ml (mean 1.6 + 
1.3 yg/100 ml) during the first 30 minutes after LRH administra-
tion. 
Plasma ACTH levels determined in 16 control subjects showed 
a tendency to decline from 35 + 18 pg/ml at time 0 min to 27 + 14 
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Fig. 1. Plasma ACTH (upper panel) and Cortisol (lower panel) res­
ponses to TRH (left panel) and LRH (right panel) in healthy 
adults. The shaded area represents the mean + SD. The asterisks 
(** ρ < 0.01, ***** ρ < 0.0005 Friedman's test) indicate statisti­
cal significance of the decrease between 0 and 60 min. 
if indicates statistical significance (p < 0.05 Wilcoxon's paired 
rank test) of the increase between 60 and 120 min. 
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at 10 min, 28 16 at 20 min, 28 + 19 at 30 min, and 25 + 11 pg/ 
ml at 60 min ( p x x x < 0.10). Between 60 and 120 min a slight, 
though significant (p x < 0.05) increase of ACTH occurred, concur-
ring with the rise in plasma Cortisol during the same time-inter-
val . 
PATIENTS WITH CUSHING's DISEASE (Fig. 2 and 3 ) . 
Because several subjects in the control group showed a slight 
increase of plasma Cortisol levels after administration of each 
of the releasing hormones, especially after TRH, an increase excee-
ding 6.0 yg/100 ml (mean + 3 S D ) , present at least at 2 time in-
tervals within the first 30 min after loading, was chosen to deli-
neate paradoxical responsiveness to a releasing hormone. 
Response of Cortisol and ACTH to TRH. 
In 6 of the 23 Gushing patients the rise of plasma Cortisol 
within 30 min after TRH loading fulfilled the criterion stated 
above for paradoxical responsiveness. In these 6 patients the 
mean plasma Cortisol levels increased from 16.7 + 6.8 yg/100 ml 
at time 0 to 26.2 + 7.9 at 10 min, 29.4 + 10.1 at 20 min and 31.2 
+ 12.7 ug/100 ml at 30 min ( p x x x < 0 . 0 1 ) . Thereafter plasma 
Cortisol levels fell to 20.6 + 7.6 ug/100 ml at 60 min and 16.7 
+ 6 . 9 ug/l00 ml at 120 min. 
In four of the TRH responsive patients, in whom ACTH levels 
were measured, these levels increased without exception from a 
mean of 93 + 63 pg/ml (range 32 to 180 pg/ml) at time 0, to 364 + 
299 pg/ml (range 120 to 750 pg/ml) at 10 minutes. 
In the remaining 17 patients with Cushing's disease plasma 
Cortisol levels remained virtually unchanged throughout the test. 
In 7 of these 17 TRH non-responsive patients in whom ACTH levels 
were measured, these levels also remained virtually unchanged. 
Response of Cortisol and ACTH to LRH. 
In 6 of the Gushing patients the rise of plasma Cortisol after 
LRH loading fulfilled the criteria of paradoxical responsiveness. 
In these patients the mean plasma Cortisol levels rose from 14.5 
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Fig. 2. Plasma ACTH (upper panel) and Cortisol (lower panel res-
ponse to TRH (left panel) and LRH (right panel) in patients with 
Cushing's disease, responsive to releasing hormone administration 
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Fig. 3. Plasma ACTH (upper panel) and Cortisol (lower panel) 
response to TRH (left panel) and LRH (right panel) in patients 
with Cushing's disease not responding to the administration of 
releasing hormones 
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+ 5.4 yg/lOO ml at time 0, to 23.2 + 7.9 at 10 m m , 31.2 + 18.5 
at 20 min and 30.5 + 12.7 at 30 m m ( р Ж Х Х < 0.001). Thereafter, 
plasma Cortisol levels fell to 29.7 + 10.9 ug/100 ml at 60 m m 
and 26.8 + 10.9 pg/100 ml at 120 minutes. 
In five of the LRH responsive patients in whom ACTH levels 
were measured, these levels rose without exception from 99 + 53 
pg/ml (range 52 to 184 pg/ml) to a maximum of 509 + 530 pg/ml 
(range 93 to 1400 pg/ml) at 10 minutes. 
In the remaining 17 patients Cortisol levels remained virtual­
ly unchanged. In 10 of these LRH non responsive patients in whom 
ACTH levels were measured, these levels also remained unchanged. 
Response of plasma Cortisol and ACTH to TRH and/or LRH. 
A paradoxical increase of Cortisol in response to TRH and/or 
LRH was present in 9 patients with Cushing's disease (group I). 
Three of these 9 patients showed a paradoxical response to both 
releasing hormones, 3 to LRH alone and 3 to TRH alone. In 6 of 
these 9 patients a control study was performed by the administra­
tion of a bolus injection of 1 ml saline 0.9%. None of these sham 
tests fulfilled the criterion put forward for paradoxical respon­
siveness. The mean values + SD of Cortisol levels were at -30': 
15.0 + 4.0 ug/100 ml, at time 0: 13.1 + 2.9, at 10 m m : 13.5 + 
4.7, at 20 m m : 13.9 + 3.8, at 30 m m : 12.4 + 5.5, at 60 m m : 11.4 
+ 6.6 and at 120 m m : 11.4 + 6.6 ug/100 ml. 
The remaining 14 patients showed no paradoxical response to 
either releasing hormone (group II). In the responder patients 
a statistically significant correlation was found between the 
X X 
maximum ACTH and Cortisol increases (r = 0.78, ρ = 0.02). 
In 3 paradoxically responding patients, multiple (n = 16) tests 
were performed before treatment of their Cushing's disease. At all 
occasions paradoxical increments of Cortisol and/or ACTH were ob­
tained again. In one non-responsive patient tested at 2 occasions 
all tests consistently showed non-responsiveness. 
COMPARISON OF CLINICAL AND BIOCHEMICAL DATA IN RESPONSIVE AND NON-
RESPONSIVE PATIENTS. 
Clinical data (table 1 ) . 
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There were no statistically significant differences between 
both groups in either age (39 + 8 yr in group I vs 39 + 12 yr in 
group I I ) , sex distribution (group I: 2 men, 7 women, group II: 
* 3 
2 men, 12 women) or sellar volume (1634 + 874 mm in group I vs 
1263 + 675 mm in group I I ) . An enlarged sella was present in 5/9 
patients of group I and 5/14 of group II and radiological evidence 
of sellar destruction in 2 patients of group I and one of group II. 
There was no statistically significant difference in duration 
of disease between both groups (2.7 + 2.7 yr in group I vs 3.5 + 
3.0 yr in group I I ) , however, in only 1 out of 9 patients of group 
I the duration of the disease was more than two years against 
7 out of 14 patients of group II ( p x x x x < 0.10). 
Biochemical data (table 1) 
Basal plasma Cortisol and ACTH levels. 
In the responder group, the mean basal ACTH level (derived 
from the mean of 4 samples taken at 08 hr in each individual) was 
significantly lower (p < 0.02) than in the non-responder group 
(89 + 28 pg/ml in group I vs 185 + 164 pg/ml in group I I ) . Remark­
ably, the mean basal plasma Cortisol levels (also derived from 
the mean of 4 determinations in each individual) did not differ 
significantly between the 2 groups: 18.5 + 5.8 pg/100 ml in group 
I vs 20.3 + 7.3 yg/100 ml in group II. 
Diurnal variability of Cortisol in the 2 groups of patients. 
When the plasma Cortisol levels during the day at each time 
interval were expressed as the percentage of the mean value for 
each individual, the amplitude of daily Cortisol variability could 
be calculated according to the formula A ma*% \ Δ 'ηιπ%. The ampli­
tude of Cortisol variability throughout the day (25 + 8%) was sig­
nificantly lower (p < 0.02) in group I than in group II (36 + 1 3 % ) . 
Furthermore, 9 out of 14 Gushing patients in group II had the 
highest plasma Cortisol values between 8 and 12 hr against only 
3 out of 9 in group I. Only in group II, there was a tendency to 
a diurnal decrease of plasma Cortisol levels between noon and 04 
hr ( p X < 0.10) (Fig. 4 ) . 
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Fig. 4. Mean percentage Cortisol variability at the various 
points of time obtained by the formula 
Δ max % - h min % . . ., 
* (see text) 
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Table 1: CLINICAL AND BIOCHEMICAL DATA IN 23 PATIENTS WITH 
CUSHING's DISEASE. 
^tient age sex menopausal duration sellar sellar 
NO (yr) status of volume destruc-
disease mrr tion 
{yr ) 
дстн 
pg/ml 
CORTISOL (ид/100 ml) 
dexamethasone 
2 mg 4xJ mi 4x2 mc 
normal 
values <1100 '20 
45 
24 
41 
49 
43 
34 
35 
45 
33 
pre 
pre 
post 
pre 
pre 
285T 
980 
1568 
1254 
1440 
924 
924 
103 
75 
84 
123 
73 
48 
141 
73 
83 
25 7 
16 3 
16 7 
27 3 
15 1 
9 8 
23 6 
16 0 
14 5 
20 0 
6 9 
1 5 
26 5 
4 4 
8 3 
3 6 
2 5 
35 6 
2 2 
1 1 
13 1 
15 2 
mean 39 
SO П 
2 7 
2 7 
1634 
874 
89 
28 
8 5 
5 8 
12 7 
11 9 
14 5 
8 7 
8 0 
11 3 
27 
36 
48 
34 
17 
31 
60 
35 
26 
45 
47 
56 
39 
44 
pre 
pre 
post 
pre 
pre 
pre 
post 
pre 
pre 
pre 
pre 
f pre 
5 
1 
2 
1 
2 5 
3 
1 
1 
3 
>10 
5 
1 
40 
3 
1320 
945 
1238 
945 
847 
1078 
1056 
1260 
1080 
3128 
1050 
1666 
600 
54 
146 
116 
151 
66 
110 
700 
2 5 0 
2 1 7 
126 
1 9 8 
2 6 9 
1 3 8 
1 5 0 
14 5 
22 5 
21 8 
16 0 
14 9 
18 2 
19 6 
25 4 
25 8 
19 6 
12 0 
40 7 
14 9 
16 3 
29 8 
20 0 
10 5 
6 9 
11 6 
6 5 
14 5 
16 0 
20 3 
4 0 
13 1 
14 5 
26 8 
20 7 
6 2 
24 7 
37 8 
11 3 
2 2 
3 3 
19 6 
2 9 
14 5 
5 8 
22 9 
2 5 
5 4 
7 6 
43 2 
5 4 
1 6 
mean 39 
SD 12 
3 5 
3 0 
1 2 6 3 
6 75 
185 
164 
20 3 
7 3 
16 3 
9 8 
10 9 
11 6 
6 6 
6 0 
23 0 
9 5 
•Jfr ρ < 0 02 (Wilcoxon s two sample t e s t ) vs responders 
Dexamethasone suppressibi1 ity (table 1 ) . 
There was no difference in Cortisol suppressibi1 ity between 
both groups of Cushing patients. The mean plasma Cortisol levels 
were similar after 2 mg overnight dexamethasone administration 
(12.7 + 11.9 ug/100 ml in group I vs 15.2 + 8.4 yg/100 ml in group 
II, ρ > 0 . 1 0 ) , in the low (14.5 + 8.7 vs 16.3 + 9.8 yg/100 ml, 
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ρ > 0.10) and high dose (8.0 + 11.3 yg/lOO ml vs 10.9 + 11.6 yg/ 
100 ml, ρ > 0.10) dexamethasone suppression test. 
Response of plasma Cortisol to bromocriptine (Fig. 5 ) . 
After bromocriptine, plasma Cortisol levels in group I chang­
ed from 14.8 + 6.2 ug/100 ml at 8 hr, to 11.2 + 1.8 ug/100 ml at 
9 hr, 10.9 + 3.6 yg/100 ml at 10 hr, 14.8 + 6.2 yg/100 ml at 11 
hr and 16.3 + 9.8 yg/100 ml at 12 hr ( p X X X > 0.10). Only in one 
of the 5 patients tested in group I (nr 1 ) , the suppressive effect 
of bromocriptine was statistically significant ( p x x < 0.05). 
In group II bromocriptine was rather ineffective too. In this 
group plasma Cortisol levels changed from 23.6 + 8.0 yg/100 ml at 
8 hr, to 21.8 + 11.6 yg/100 ml at 9 hr, 21.8 + 12.3 ug/100 ml at 
10 hr, 20.7 + 10.5 at 11 hr and 18.2 + 6.9 yg/100 ml at 12 hr 
(p x > 0.10). In this non-responder group 2 out of the 11 pa­
tients tested showed a significant ( p x x < 0.05) suppression of 
plasma Cortisol levels after bromocriptine. 
Prolactin (table 1 ) . 
Basal prolactin levels did not differ between both groups 
(6.8 + 4.8 ng/ml in group I vs 6.6 + 6.0 ng/ml in group I I ) . 
Hyperprolactinaemia was present in no patient of group I and in 
1 patient of group II. The basal prolactin levels did not differ 
from the values of the control group (4.3 + 2.4 ng/ml). The res­
ponse of prolactin to TRH was almost similar in both groups (Δ 
max. 21.4 + 17.5 ng/ml in group I vs 23.0 +_ 9.5 ng/ml in group II, 
ρ > 0.10). These responses of prolactin to TRH in the Gushing 
patients did not differ significantly from those of the control 
group (Δ max. 26.1 + 11.4 n g / m l ) . 
DISCUSSION 
The present study is the first to demonstrate systematically 
a paradoxical increase of Cortisol even to twice the baseline 
value, in response to either TRH or LRH or both peptides in about 
40X (9 out of 23) of a series of consecutive patients with active 
Cushing's disease. The rise in Cortisol was preceded by a tran-
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Fig. 5. Plasma Cortisol levels after the oral administration of 
5 mg bromocriptine in patients with Cushing's disease, upper panel 
patients responding to TRH/LRH and lower panel: patients non 
responsive. * : values significantly (p < 0.05) decreasing in an 
individual patient. 
• · individual values · — · mean values 
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sient 4-to 5-fold increase of immuno-assayable ACTH at 10 minutes 
after administration of the releasing hormone. These data con­
trast with those of Connell et al (40) and Matsukura et al (3) 
who failed to find such a response of ACTH or Cortisol in a few 
patients with treated or untreated Cushing's disease, and are 
also at variance with data of Krieger et al ( 1 ) , who did find a 
paradoxical Cortisol response to TRH in each of б patients and an 
ACTH response in all three patients studied. After measuring Cor­
tisol responses to TRH and LRH in a fair number of normal control 
subjects, we formulated rather stringent criteria for Cortisol 
responsiveness to TRH and LRH and according to our definition 3 
of the 9 showed a paradoxical response to both TRH and LRH, 3 
only to TRH, and another 3 only to LRH. After defining a responder 
and a non-responder group, we searched for clinical and biochemi­
cal differences between these two subsets of patients with Cushing' 
s di sease. 
From the clinical point of view, we could not find, so far, 
meaningful differences, albeit that the mean sellar volume was 
somewhat larger and the mean duration of the disease somewhat shor­
ter in the responder group compared with the non-responders. The 
immunoassayable ACTH (I-ACTH) levels in the responder group were 
significantly lower than in the non-responders, whereas the basal 
plasma Cortisol levels did not differ. 
Another, more intriguing difference between the two groups 
was found in studying the spontaneous fluctuations of the plasma 
Cortisol levels over the day. In fact the responder group showed 
less variability as shown in the results section. We do not have 
a simple explanation for this difference. The smaller amplitude 
in the responder-group favours the existence of a more tonic re­
lease of ACTH against a more episodic type of release in the non-
responders. Unfortunately, no data on ACTH levels throughout the 
day are available to substantiate this hypothesis. 
So far, TRH mediated ACTH release has been reported only in 
animal species with a wel 1-deve!oped intermediate lobe and in preg­
nant women with a supposedly active pars intermedia. One could 
wonder therefore, whether patients with Cushing's disease who pa­
radoxically respond to aspecific releasing hormones, in fact 
would have neoplasia or hyperplasia of intermediate lobe cortico-
86 
trophs, whereas the non-responder patients would have an adenoma 
of the anterior lobe of the pituitary. Lamberts et al (4, 2 9 ) , on 
the strength of histological investigations of surgically removed 
pituitary tumours, discerned between intermediate lobe and ante-
rior lobe overproduction of ACTH to discriminate two subsets of 
patients with Cushing's disease. They reported in addition, that 
these subsets differed from each other by three other characteris-
tics, I: intermediate lobe Gushing patients were relatively less 
suppressible by dexamethasone. II: These patients had higher pro-
lactin levels and III: Bromocriptine led to more suppression of 
ACTH and Cortisol. Our 9 responder-patients did neither differ 
from the 14 non-responders in suppressibi1 ity of adrenocortical 
function by dexamethasone, nor in basal prolactin levels or TRH 
stimulated prolactin 1evels .whereas bromocriptine proved equally 
ineffective to lower plasma Cortisol levels in either group. There-
fore our data do not favour intermediate lobe hypersecretion of 
ACTH to provide a plausible explanation for the paradoxical ef-
fects of TRH and/or LRH in the subset of responding patients with 
Cushing's di sease. 
Recently Peck et al (41) demonstrated that mouse pituitary 
tumour cells responding in vitro to TRH with release of ACTH have 
binding sites for this releasing hormone, whereas such receptors 
lack in anterior pituitary cells derived from normal rats. 
Ishibashi et al (8) studied human corticotroph adenoma cells 
of patients with Nelson's syndrome in vitro. These cells, which 
released ACTH in response to TRH, were still responsive to gluco-
corticoids. The suppressive effect of glucocorticoids on ACTH re-
lease could be easily overcome by equimolar concentrations of TRH. 
These findings are in concert with our observation that glucocor-
ticoid suppress!bi1 ity is preserved despite responsiveness to TRH. 
To summarize, the present study demonstrates that ACTH and 
Cortisol responsiveness to TRH and LRH discloses the presence of 
two distinct groups of patients with Cushing's disease. In two of 
our patients who were at a beginning stage of their disease, with 
only slightly disturbed dexamethasone suppressibi1 ity, the presen-
ce of a paradoxical response to TRH and/or LRH was very helpfull 
in making the correct diagnosis. It has to be settled yet, whether 
TRH and LRH responsiveness as described, has implications for the 
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prognosis and the way of treatment of these patients, since after 
pituitary surgery Cushing's disease persisted in all 3 paradoxi-
cal responding patients, whereas 4 out of 5 non responding pa-
tients were cured. 
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CHAPTER VI 
COMMENT 
§ 1. Acromegaly. 
In chapter II a tight connection is demonstrated between the 
inhibitory effect of SRIF and the stimulatory effect of LRH on hGH 
levels in patients with acromegaly. During the last year, we studied 
7 more patients with acromegaly, 5 of whom showed normalization of 
hGH levels during the administration of 300 micrograms SRIF per 
hour. Three of these 5 SRIF-normali zing patients showed paradoxical 
increases of hGH levels after the administration of LRH. The 2 pa­
tients, whose hGH levels did not normalize during SRIF administra­
tion, showed no responsiveness to LRH. Together with the data 
reported in chapter II the incidence of LRH-responsiveness in the 
SRIF-normali zing patients is 8 out of 13 and in the SRIF non-norma-
lizers 0 out of 14 (χ 2: Ρ < 0.005). 
Furthermore,we studied the effect of concomitant administra­
tion of SRIF on the hGH responsiveness to LRH in 3 LRH responsive 
acromegalic patients. The results in figure 1 show that the -
albeit small -increments of hGH to LRH in 2 patients disappear 
completely during SRIF (300 yg/hr) administration and the response 
of the third patient is reduced to about 40%. These findings are at 
variance with those of Giustina et al (l),who reported no effect 
of SRIF on hGH responsiveness to LRH in 2 acromegalic patients. 
These authors in addition studied the effect of SRIF on TRH-induced 
hGH release in 3 patients with acromegaly. They showed that SRIF 
did not abolish such paradoxical hGH response. Other investigators 
confirmed this observation ( 2 ) . All together our data suggest that, 
with regard to LRH induced paradoxical hGH release, a direct anta­
gonism between SRIF and LRH indeed exists. 
Besser et al (3) studied the effect of SRIF administration on 
95 
hGH n g / m l 
120 π 
100-
8 0 -
6 0 -
Д0 
2 0 -
LRH100Y ι ν 
100 л 
8 0 -
6 0 
Д 0 -
2 0 
60 9 0 120 
t i m e ( m i n ) 
F i g . 1 . hGH responses t o LRH i n 3 p a t i e n t s w i t h acromegaly ( u p p e r 
p a n e l ) . In t h e lower panel hGH responses t o LRH d u r i n g concomi­
t a n t SRIF a d m i n i s t r a t i o n i n t h e same p a t i e n t s are d e p i c t e d . 
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the paradoxical hGH rise to glucose loading, which occurs in a 
subgroup of the acromegalic population and found that SRIF inverts 
the paradoxical hGH rise to glucose into a regular decline. From 
their observations, the investigators deduced that in these acro-
megalics a primary SRIF-deficiency existed and that this SRIF-defi-
ciency might be the cause of the occurrence of a paradoxical hGH 
rise in response to glucose loading. Furthermore, they suggested 
that in normal physiology a rise of blood glucose induces SRIF 
release, which in turn decreases hGH release. Under physiological 
conditions, glucose induces paradoxical hGH release in neonates and 
in pubertal boys and girls about the time at which ejacularche or 
menarche occurs, which observation our group was the first to 
report ( 4 ) . Referring to the above-mentioned explanation of the 
effect of SRIF deficiency on glucose-induced hGH release in some 
acromegalics, one might wonder whether the observed glucose-induced 
paradoxical hGH-release at the time of pubertal growth-spurt is an 
example of physiological SRIF deficiency. Suggesting a direct anta-
gonism between SRIF and LRH, such SRIF deficiency in puberty might 
be the inducer of unopposed LRH-release leading to gonadotropin 
production and of hGH-release, together priming growth and sexual 
development. 
§ 2. Cushing's disease. 
Studying possible differences between TRH/LRH responsive and 
non-responsive patients with Cushing's disease, we reported in 
chapter V that the immunoassayable ACTH levels (I-ACTH) in the 
responder group were significantly lower than in the non-respon-
ders. In that study, it has not been reported that (in addition) 
bioassayable ACTH levels (B-ACTH) were determined according to the 
method of Goverde (5) in a number of the observations.In 7 respon-
ders,B-ACTH levels increased about tenfold after TRH or LRH,whereas 
I-ACTH rose about fivefold. The basal levels of B-ACTH did not dif-
fer between the responders and the non-responders in concert with 
the lack of difference between the Cortisol levels of both groups. 
From these data one might infer, that the difference in the basal 
I-ACTH levels between the responders and the non-responders is caused 
by a larger amount of biologically inactive ACTH-like material in 
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the blood of the latter group. It has been demonstrated that the 
biological activity of immunoassayable ACTH (expressed as the B/I 
ratio) in the intermediate lobe is higher than in the anterior 
lobe ( 6 ) . Therefore one of the explanations for the difference 
in B/l ratio between both responding and non-responding patients 
with Cushing's disease might be an intermediate lobe origin in 
the former group. In chapter V our objections against this hypo­
thesis were given (page 8 7 ) . 
In order to further resolve this apparent dilemma,we asked 
Drs Lamberts and Stefanko (7) to investigate histologically the 
pituitary tissue of our patients who underwent neurosurgery to 
discern (according to their standards) between intermediate and 
anterior lobe origin of Cushing's disease.They classified a total 
number of 7 specimens of pituitary tissue from an equal number 
of patients (tabi e I ) . 
Table I: Classification of surgically removed pituitary tissue 
in 7 patients with Cushing's disease by Drs Lamberts 
and Stefanko 
patient number 
cfr chapter V.table 1 
1 
S-
<u 
? 5 
о 
Q. 
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classification 
anterior lobe 
intermediate lobe 
intermediate lobe 
anterior lobe 
intermediate lobe 
not classifiable 
anterior lobe 
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In our opinion the data in the table do not allow to conclude 
either that patients with TRH/LRH responsive Cushing's disease are 
those with an intermediate lobe origin, or that patients with 
TRH/LRH nonresponsive Cushing's disease are those with an anterior 
lobe ori gin. 
We entertain two other possible explanations for the existance 
of responsiveness and non-responsiveness to TRH/LRH in patients 
with Cushing's disease. 
i. Cushing's disease is a primary pituitary disorder caused by 
the development of an adenoma of corticotrophs. A small number of 
these adenomas have receptors for TRH and/or LRH, whereas in most 
adenomas these are lacking. Therefore most patients with Cushing's 
disease are non-responder. 
ii. Cushing's disease is in origin a hypothalamic disorder 
leading to hyperplasia of the ACTH producing cells of the hypophy­
sis, not confined to the anterior lobe, but also present in other 
parts of the hypophysis and in the pituitary stalk up to the re­
gion of the pars tuberalis (8, 9, 1 0 ) . The primary hypothalamic 
disorder might be either absolute overproduction of CRH or the 
deficiency of a physiological inhibitor of ACTH production (in 
this context substances such as dopamine and γ amino-butyric-
acid might be m e n t i o n e d ) . In case of primary CRH-excess, paradox­
ical secretion of ACTH by TRH and/or LRH might not be expected 
because the corticotrophs are already maximally stimulated. There­
fore these patients expectedly will be non-responders. In this 
hypothesis one still has to explain the occurrence of paradoxical 
rises of ACTH and Cortisol in response to TRH and/or LRH in the 
remaining patients. It seems appropriate to remind of the lower 
basal I-ACTH levels in the responders. In chapter II, we described 
that acromegalics whose hGH levels could be normalized by the 
administration of SRIF, predominantly responded with a paradoxical 
rise of hGH after the administration of LRH. In these SRIF-respon-
ders, the basal hGH levels were significantly lower than in the non-
responders. Together these data lead us to suppose that these pa­
tients have a primary deficiency of endogenous SRIF. By analogy 
we suppose, that patients with Cushing's disease who respond para­
doxically to TRH and LRH and whose basal ACTH levels are lower 
than in the non-responders, could be deficient in a natural inhi-
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bitor of ACTH production. 
So far, as reported in chapter V, 8 patients underwent pituitary 
surgery: 4 out of 5 non-responders were cured, whereas none of the 
3 responders showed a remission of their disease. 
With all proper proviso we interpret the above-mentioned diagnos-
tic and therapeutic data as follows: 
i. Patients with Cushing's disease who do not respond to TRH 
or LRH are most likely patients with an adenoma of corticotrophs. 
In these patients selective pituitary surgery might be expected 
to cure Cushing's disease. 
ii. Patients who show a paradoxical increase of ACTH/cortisol 
in response to neuropeptides such as TRH and/or LRH,have a primary 
hypothalamic disorder. In these patients cure of Cushing's disease 
by selective pituitary surgery can not be expected. 
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SUMMARY. 
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stration ( "responders"). 
The tight connection between the responses of hGH to bromo-
cryptine and to TRH has led to the suggestion that there are 
two different forms of acromegaly. In chapter I we hypothesize 
that the acromegaly of the "responders" has a primary hypothala-
mic origin whereas in the non-responders a primary pituitary 
cause has to be assumed. Several authors suggested that primary 
deficiency of somatostatin (SRIF) might be the underlying cause 
in the hypothalamic form of acromegaly. Therefore we investigated 
whether the administration of exogenous SRIF could lead to the 
delineation of a subgroup of patients with acromegaly, which is 
more sensitive to this peptide. The results of this investigation 
are given in chapter II: Twenty patients with acromegaly were 
given increasing dosages of SRIF intravenously. Eight of these 
20 patients showed normalization of their hGH levels during SRIF 
infusion (group I) whereas the hGH levels of the other 12 patients 
remained elevated (group I I ) . The basal hGH levels in group I were 
significantly lower compared to group II. Glucose tolerance was 
significantly more impaired in patients of group II. Their were 
no differences between both groups in the frequency of occurrence 
of paradoxical hGH responses to TRH. Remarkably both groups did 
differ in the occurrence of paradoxical hGH responses to LRH: 5 
out of 8 patients in group I showed such anomalous response, 
whereas none of the 12 patients in group II responded paradoxical-
ly to LRH. In contrast to most literature data no differences 
were found between both groups in the frequency of normalization 
of hGH levels after bromocriptine administration: 4 out of 8 
patients in group I showed normalization of hGH levels after 
bromocriptine administration against 5 out of 12 patients in group 
II. The conclusions of this study are: a) There is a subgroup of 
patients with acromegaly who is more sensitive to exogenous SRIF. 
Perhaps these patients have a primary deficiency of endogenous 
SRIF as the cause of their acromegaly, b) Only these patients 
show paradoxical hGH response to LRH. c) SRIF sensitivity does 
not cover bromocriptine sensitivity. The discongruence between 
the effects of these agents may have therapeutic implications. 
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The phenomenon of paradoxical hGH responses to TRH and to LRH 
in acromegaly led us to investigate if such paradoxical responses 
also occur in other forms of hyperpituitarism. In 1976 we started 
to investigate whether TRH and LRH affect the release of ACTH and 
Cortisol in patients with Cushing's disease. Shortly thereafter 
scarce controversial data on this subject appeared in literature. 
In the second part of chapter II these data are discussed. Fur­
thermore the possibility has been put forward that paradoxical 
responses of ACTH/cortisol to TRH are only present when the pitui­
tary contains a well developed intermediate lobe. It is well known 
that in the human this part of the hypophysis disappears after 
birth, which might explain why healthy humans do not show para­
doxical responses of ACTH and Cortisol to TRH. In most animal 
species, in contrast to man, the intermediate lobe of the hypo­
physis does not disappear after birth. By studying the processing 
of ACTH and ACTH-related peptides from the pro-opiolipomelano-
cortin in the pars intermedia and in the pars anterior differences 
in the synthesis and the regulation of release of hormones between 
these parts of the pituitary were found: Only in the anterior 
lobe the negative feed-back of glucocorticoids and the releasing 
effect of corticotropiη-releasing hormone on ACTH and ACTH-related 
peptides are operative, whereas the hormone secretion of the 
intermediate lobe is under direct neural control. The recent 
demonstration of histochemical signs of hyperplasia of the vesti-
geal intermediate lobe in some humans with Cushing's disease, 
points to the posibility that some patients with this disease 
have a primary intermediate lobe origin of their disease, whereas 
the others have a primary anterior lobe origin. The secretion 
of a-melanocyt stimulating hormone (a-MSH) - which is a typical 
intermediate lobe peptide - by some pituitary tumors of patients 
with Cushing's disease also points to this possibility. The 
existence of paradoxical ACTH responses to TRH in animals whose 
pituitary contains an intermediate lobe suggest that this para­
doxical responsiveness only is present in patients with "inter­
mediate lobe" Cushing's disease. 
As stated above we started our investigation to paradoxical 
responses of ACTH and Cortisol to TRH and to LRH in patients 
with Cushing's disease from another point of view. In chapter III 
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the results are given of the first 6 patients who were studied. 
Three of these б patients showed paradoxical responsiveness of 
Cortisol to TRH as well as to LRH. In the remaining 3 patients 
Cortisol levels did not increase after TRH or LRH but also did 
not decline as they did in healthy humans. 
In the introduction of chapter IV some arguments are given 
from which one can derive that the intermediate lobe of pregnant 
women regains its activity. Furthermore the altered regulation of 
ACTH and Cortisol secretion in pregnancy which is comparable to 
the changes in hormone secretion in Cushing's disease is stressed: 
In pregnant women basal ACTH and free Cortisol levels are higher 
than in controls, furthermore suppressibi1 ity of Cortisol levels 
by dexamethasone is deminished. Therefore we investigated - after 
we had observed fortuitously a paradoxical Cortisol response to 
TRH in 1 pregnant woman - the reaction of ACTH and Cortisol in 
response to TRH in 7 pregnant women. Six of these 7 pregnant women 
showed a clear increase of Cortisol levels, whereas 4 out of 5 
subjects tested also evinced a rise in ACTH levels, preceeding the 
Cortisol increase. Seven other pregnant women were given an injec­
tion of saline instead of TRH. In none of these women paradoxical 
increases of ACTH or Cortisol were observed. Seven healthy non­
pregnant women who used conventional oral contraceptives also did 
not respond paradoxically to TRH. These data supported our assump­
tion that an active pars intermedia is a prerequisite for para­
doxical responsiveness of ACTH and Cortisol to TRH. 
Meanwhile the number of patients with Cushing's disease inves­
tigated for their responsiveness to TRH and LRH had been enlarged 
(chapter V ) . From the data obtained in a representive control 
group we derived a criterion for paradoxical responsiveness of 
Cortisol in response to a releasing hormone:an increase of Cortisol 
levels exceeding 6.0 ug/100 ml, present at least two times within 
30 minutes after the administration of the releasing hormone. 
According to this criterion 9 out of 23 patients with Cushing's 
disease responded paradoxically (group I ) . From these 9 patients 
3 responded paradoxically to both TRH and LRH, 3 to TRH alone and 
3 to LRH alone. The remaining 14 patients (group II) did neither 
show paradoxical responsiveness to TRH nor to LRH. 
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After the delineation of these two subgroups we searched after 
differences between both groups which could indicate a dissimila-
rity in the origin of their disease: from the data mentioned 
above one would expect that patients of group I show characteris-
tics of "intermediate lobe Cushing's disease", whereas group II 
should show signs of "anterior lobe Cushing's disease". If this 
were true one would expect that Cortisol levels of patients of 
group I are less suppressible by dexamethasone. Furthermore the 
suppressive action of dopaminergic drugs like bromocriptine 
should be more expressed in patients of group I. Lastly, as was 
demonstrated by Lamberts et al, one would expect higher basal 
prolactin levels in the patients of group I. In chapter V it is 
described that group I and group II did not differ from each 
other in any of these characteristics. Both groups did differ 
however in the basal levels of (immuno-assayable) ACTH levels: 
patients of group I had significantly lower basal levels compared 
to group II. Remarkably basal Cortisol levels did not differ be-
tween both groups. In the comment (chapter VI) we mention our 
data on the biological activity of ACTH in the patients with 
Cushing's disease. Although these data are scarce they do not 
point to a statistical difference in basal levels of biologically 
active ACTH between both groups. From these data one could derive 
that the ACTH of the paradoxically responding patients has a rela-
tively higher biological activity, which could argue for a diffe-
rent origin of the ACTH hypersecretion between both groups. It is 
known that the ACTH from the pars intermedia has a higher biolo-
gical activity than the ACTH from the pars anterior. Besides the 
difference in basal ACTH levels, both groups did differ still in 
another way: the variability of Cortisol levels during the day and 
night was significantly less pronounced in the paradoxically res-
ponding patients.We do not have an explanation for this difference. 
Nevertheless the differences found between both groups attribute 
to the discrimination of two subsets of patients with Cushing's 
disease on the strength of the response of ACTH and Cortisol to 
TRH/LRH. 
Until! now 8 of our 23 patients with Cushing's disease under-
went pituitary surgery: 3 "responders" and 5 "non-responders". In 
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all 3 "responders" Cushing's disease was still active after surge-
ry whereas it was cured in 4 of the 5 non-responding patients. 
These preliminary data suggest that the presence or absence of 
paradoxical responses to TRH and LRH may have a prognostic value 
for the treatment of Cushing's disease. The pituitary tissue 
obtained at operation was investigated by Lamberts and Stefanko, 
who could discriminate, on histochemical grounds, between an ante-
rior lobe and an intermediate lobe origin of Cushing's disease. 
The results of their investigation on the pituitary tissue in our 
patients however, does not permit to conclude that patients with 
Cushing's disease who paradoxically respond to TRH/LRH are those 
with an intermediate lobe origin, or that patients who do not 
respond to TRH/LRH are those with an anterior lobe origin. 
In chapter VI we finally hypothesize: 
i) Patients with Cushing's disease who do not respond paradoxi-
cally to the administration of TRH/LRH are patients with a 
(micro)adenoma of the ACTH producing cells. These patients 
are expected to be cured by selective pituitary surgery. 
ii) Patients who show paradoxical responsiveness of ACTH/cortisol 
to TRH/LRH have a primary hypothalamic derangement that leads 
to hyperplasia of the ACTH producing cells. In these patients 
selective pituitary surgery will not be succesful . 
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PARADOXALE REACTIES OP DE TOEDIENING 
VAN HYPOTHALAME RELEASING HORMONEN 
SAMENVATTING 
Het is reeds langer bekend dat bij patiënten met akromegalie 
na de toediening van de releasing hormonen "Thyroid stimulating 
hormone releasing hormone" (TRH) en "Luteinizing hormone releasing 
hormone" (LRH) paradoxale stijgingen van de spiegels van groeihor-
moon in het bloed kunnen optreden. In dit proefschrift wordt dit 
verschijnsel verder onderzocht. Daarnaast wordt aangetoond dat een 
dergelijk verschijnsel ook voorkomt bij een andere vorm van hyper-
pi tui tari sme , de ziekte van Cushing, in dit geval: paradoxale 
stijgingen van de spiegels van adrenocorticotropine (ACTH) en 
Cortisol na de toediening van genoemde releasing hormonen. 
In hoofdstuk I wordt beknopt de geschiedenis van de ontdekking 
van TRH, LRH en andere "releasing" of "release-inhibiting" hormon-
nen van de hypothalamus beschreven. Speciale aandacht wordt ge-
schonken aan de specificiteit van de effecten van deze peptiden, 
zowel in physiologische als in pathologische omstandigheden. Het 
is gebleken dat bij akromegalie deze specificiteit vaak verminderd 
is. Bij deze ziekte immers blijkt TRH niet alleen de afgifte van 
schildklier stimulerend hormoon en prolactine te bevorderen, en 
LRH niet alleen die van de gonadotropi nes (LH en F S H ) , maar dat 
deze peptiden dan ook groeihormoon kunnen vrijmaken. Dergelijke 
aspecifiek opgeroepen antwoorden worden, wellicht niet geheel te-
recht, in het algemeen "paradoxical responses" genoemd. Een derge-
lijke paradoxale reactie van groeihormoon op TRH werd niet alleen 
bij akromegalie, maar ook bij diverse andere ziekten beschreven 
(diabetes mellitus, anorexia nervosa, ni erinsufficientie, chroni-
sche 1everziekten , orimaire hypothyreoidi e en endogene d e p r e s s i e ) . 
Bovendien wordt er op gewezen dat bij akromegalie de spiegels van 
groeihormoon ook paradoxaal kunnen stijgen na toediening van glu-
cose. Ook dit paradoxale antwoord werd bij een aantal andere ziek-
ten in de literatuur vermeld (prediabetes mellitus, ondervoeding, 
anorexia nervosa, m'erinsufficientie, chronische leverziekten , 
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syndroom van Turner, acute intermitterende Porphyrie en ook bij 
pasgeboren k i n d e r e n ) . In dit verband wordt er ook op gewezen dat 
in een eigen onderzoek dit verschijnsel zich ook voordoet bij 
jongens en meisjes rond de leeftijd van de menarche en de ejacu-
1 arche. 
Het is eveneens langer bekend dat toediening van dopamine-
agonisten (zoals bromocryptine) de spiegels van groeihormoon bij 
een aantal patiënten met akromegalie kan doen dalen. Aangetoond 
werd dat dit dopaminerge antwoord zich vooral voordoet bij die 
patiënten met akromegalie, die op TRH een stijging van de spiegels 
van groeihormoon lieten zien. 
Indien er een hechte relatie tussen de aanwezigheid van deze 
beide antwoorden bestaat, zou men twee verschillende vormen van 
akromegalie kunnen onderscheiden. In hoofdstuk I wordt door ons 
gesuggereerd dat de akromegalie van de "responders" van primair 
hypothalame, en van de "non-responders" van primair hypophysaire 
oorsprong zou zijn. In de literatuur is er op gewezen dat het niet 
is uitgesloten dat de eerstgenoemde vorm van akromegalie kan worden 
veroorzaakt door een tekort aan het physiologische, onder andere in 
de hypothalamus voorkomende, groei hormoon-afgifte-remmende hormoon, 
somatostatine ( S R I F ) . Daarom startten wij in 1975 een onderzoek met 
de vraagstelling of de boven onderscheiden "responders" en "non-
responders" verschillend gevoelig waren voor exogeen toegediend 
SRIF. De resultaten van dit onderzoek worden gegeven in hoofdstuk 
II: Bij 20 patiënten met akromegalie werd een opklimmende dosering 
SRIF intraveneus toegediend. Acht van deze 20 patiënten vertoonden 
een daling van de spiegels van groeihormoon tot normale waarden 
(groep I ) , terwijl bij de overige 12 patiënten dit niet het geval 
was. In groep I was de basale groeihromoonspiegel significant lager 
dan in groep II. Ook viel op dat de glucose-tolerantie van patiën-
ten in groep I significant beter was dan die van groep II. Groep I 
verschilde niet van groep II in de frequentie van paradoxale s t i j -
gingen van groeihormoon op TRH. Wel bleek er een opmerkelijk ver-
schil tussen beide groepen te bestaan wat betreft de frequentie 
van stijgingen van groeihormoon op LRH: vijf van de 8 patiënten uit 
groep I vertoonden een paradoxale respons na LRH, terwijl geen 
enkele van de 12 patiënten uit groep II een dergelijke reactie 
liet zien. In tegenstelling tot de meeste literatuurgegevens werd 
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er geen verschil gevonden tussen de frequentie van normal ι zering 
van de groeihormoonspiegels na toediening van bromocryptine in 
beide groepen: bij 4 van de 8 patiënten uit groep I daalden de 
spiegels van groeihormoon ook na de toediening van bromocryptine 
tot normale waarden, terwijl zulks bij 5 van de 12 patiënten in 
groep II eveneens het geval was. De conclusies van dit onderzoek 
zijn: a) er is een groep patiënten met akromegalie die een hoge 
gevoeligheid voor exogeen SRIF hebben. Mogelijk hebben deze pa-
tienten een hypothalaam defect dat heeft geleid tot een tekort aan 
SRIF. b) alleen deze patiënten tonen paradoxale stijgingen van de 
spiegels van groeihormoon op de toediening van LRH. c) "responders" 
op SRIF zijn niet noodzakelijkerwijze "responders" op bromocrypti-
ne. Op de mogelijke therapeutische consequenties van deze bevinding 
wordt in hoofdstuk II gewezen. 
Het voorkomen van paradoxale reacties van groeihormoon op TRH 
en LRH bij akromegalie bracht ons er toe na te gaan of dergelijke 
paradoxale verschijnselen ook bij andere vormen van hyperpituita-
risme voorkomen. Bij de ziekte van Cushing onderzochten wij of TRH 
en LRH de afgifte van ACTH en Cortisol beïnvloedden. In 1976 
startten wij met dit onderzoek. Korte tijd nadien verschenen in de 
litteratuur een aantal mededelingen omtrent dit punt, die nogal 
controversieel waren. In het laatste deel van hoofdstuk I is hier-
aan aandacht besteed. Daarbij wordt er op gewezen dat het m e t is 
uitgesloten dat voor het optreden van paradoxale stijgingen van 
ACTH en Cortisol na de toediening van een neuropeptide als TRH de 
aanwezigheid van een goed ontwikkelde pars intermedia van de hypo-
physe een voorwaarde zou zijn. Het is bekend dat bij de mens dit 
deel van de hypophyse na de geboorte verdwijnt. Dit zou dan ook de 
reden kunnen zijn waarom bij normale mensen op toediening van TRH 
de hypophyse m e t reageert met afgifte van ACTH. Ook wordt in 
hoofdstuk I een korte samenvatting gegeven van vrij recente ontwik-
kelingen in de kennis omtrent de wijze waarop ACTH uit zijn moeder-
peptide, het pro-opiolipomelanocortine (POLMC), wordt vrijgemaakt. 
Bij de meeste diersoorten blijft de pars intermedia na de geboorte 
actief. Door bestudering van ACTH-synthese in de pars anterior en 
de pars intermedia kreeg men inzicht in de verschillende wijzen 
waarop de synthese en afgifte van ACTH en verwante peptiden in ge-
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noemde delen van de hypophyse plaats vinden. Zo kon aannemelijk 
worden gemaakt dat de remming van afgifte van ACTH door glucocor-
ticoiden en de stimulering ervan door corticotropin releasing 
hormone (CRH) alleen plaats vindt in de pars anterior. De afgifte 
van ACTH en aan ACTH verwante peptiden door de pars intermedia 
wordt geacht alleen onder invloed te staan van neurale (onder ande-
re dopaminerge) controle. Het verdient in dit verband vermelding 
dat onze landgenoot Lamberts - zoals ook door Harvey Cushing zelf 
gesuggereerd - in hypophyseweefsel van een aantal patiënten met 
de ziekte van Cushing aanwijzingen vond voor hyperplasie van 
corticotrope cellen ook buiten het areaal van de pars anterior, 
waarbij histochemisehe tekenen van neurosecretoire activiteit wer-
den aangetoond. Daaruit concludeerde hij dat de ziekte van Cushing 
bij dergelijke patiënten veroorzaakt wordt door een hyperfunctie 
van de pars intermedia. Andere onderzoekers vermoedden een derge-
lijke oorsprong van de ziekte van Cushing op andere gronden. 
Zoals gezegd startten wij om andere, eerder genoemde, redenen 
in 1976 een onderzoek naar het voorkomen van paradoxale stijgingen 
van de spiegels van ACTH en Cortisol na de toediening van TRH en 
LRH bij patiënten met de ziekte van Cushing. In hoofdstuk III wor-
den de resultaten beschreven van de reactie van Cortisol op de 
toediening van TRH en LRH bij de eerste 6 door ons daaroo onder-
zochte patiënten met de ziekte van Cushing. Bij 3 van deze patiën-
ten bleek de spiegel van Cortisol in het bloed zowel na TRH als 
na LRH paradoxaal te stijgen. Bij de overige 3 patiënten viel het 
op dat de spiegels van Cortisol na de toediening van de releasing 
hormonen in de morgen niet daalden, zoals bij mensen zonder de 
ziekte van Cushing wel het geval w a s . 
Zoals boven vermeld lijkt de aanwezigheid van een actieve 
middenkwab in de hypophyse een voorwaarde voor het optreden van een 
paradoxale stijging van ACTH en Cortisol op de toediening van TRH. 
In de inleiding van hoofdstuk IV werden een aantal argumenten ge-
noemd waaruit men kan destilleren dat bij de zwangere vrouw acti-
vering van de rudimentaire middenkwab van de hypophyse optreedt. 
Bovendien werd er (ook in hoofdstuk I) op gewezen dat de bijnier-
functie van de zwangere vrouw kenmerken vertoont van het hypophyse 
afhankelijke Cushing syndroom: hogere dan normale waarden van ACTH 
en vrij Cortisol in het bloed en onvoldoende suppressie van de 
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bijnierfunctie door dexamethason. Daarom onderzochten wij - overi-
gens nadat wij bij toeval bij één zwangere vrouw een paradoxale 
stijging van Cortisol na toediening van TRH hadden waargenomen 
(hoofdstuk I) - bij 7 gezonde zwangeren het gedrag van ACTH en 
Cortisol na de toediening van TRH. Zes van 7 zwangeren toonden een 
duidelijke stijging van de spiegels van Cortisol in het bloed. Bij 
4 van de 5 daarop onderzochte zwangeren uit deze groep nam - voor-
afgaande aan de corti solstijging - ook de concentratie van ACTH 
in het bloed toe. Een dergelijk paradoxaal antwoord werd niet 
gezien bij zwangeren die een intraveneuze injectie met physiolo-
gisch zout kregen noch bij 7 gezonde ni et-zwangere vrouwen die 
conventionele orale anticonceptiva gebruikten. Deze gegevens onder-
steunen de veronderstelling dat de activiteit van de middenkwab 
van de hyoophyse bij vrouwen in de zwangerschap - evenals bij een 
aantal patiënten met de ziekte van Cushing - de oorzaak is van het 
paradoxale reageren op TRH. 
Inmiddels hadden wij het aantal waarnemingen bij patiënten met 
de ziekte van Cushing uitgebreid (hoofdstuk V ) . Aan de hand van de 
gegevens, verkregen bij een grote groep van controle-personen, 
werden criteria voor het paradoxale reageren zorgvuldig gekozen: 
een stijging van Cortisol in het bloed van tenminste 6.0 ug/100 ml, 
tenminste tweemaal aanwezig binnen 30 minuten na de toediening van 
het neuropeptide. Volgens dit criterium bleken 9 van de 23 onder-
zochte patiënten met de ziekte van Cushing paradoxaal te reageren. 
Van deze 9 "paradoxale responders" (groep I) reageerden er 3 para-
doxaal op zowel TRH als op LRH, 3 alleen op TRH en 3 alleen op 
LRH. Veertien oatienten (groep II) reageerden niet paradoxaal op 
de toediening van TRH en/of LRH. 
Nu werd nagegaan of beide groepen zodanig van elkaar verschil-
den, dat daaruit argumenten konden worden verkregen voor een ver-
schillende ontstaanswijze in elk van beide groepen: voortbouwend 
op onze gegevens bij zwangere vrouwen zouden wij dan veronderstel-
len dat groep I kenmerken vertoont van hyperactiviteit van de 
middenkwab en dat groep II kenmerken vertoont van hyperactiviteit 
van de voorkwab. Allereerst mocht dan verwacht worden dat de 
suporimeerbaarheid van de spiegels van Cortisol door dexamethason 
in groep I meer verstoord zou zijn dan in groep II. Voorts zou 
men verwachten dat indien een dopaminerg agens als bromocryptine 
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de activiteit van ACTH bij patiënten met de ziekte van Gushing 
zou kunnen doen afnemen, deze patiënten zouden moeten behoren tot 
groep I. Tenslotte, in het licht van de gegevens van Lamberts 
(zie hoofdstuk V ) , zou men verwachten dat de spiegels van prolac-
tine in het bloed bij patiënten van groep I hoger zijn dan in 
groep II. Uit de studie, gerapporteerd in hoofdstuk V, blijkt 
dat groep I en groep II in geen van de juist genoemde eigenschap-
pen van elkaar verschilden. Wel bleken de basale spiegels van 
(immunologisch bepaald) ACTH in groep I significant lager dan in 
groep II. Merkwaardigerwijze verschilden de basale spiegels van 
Cortisol tussen beide groepen niet. In ons commentaar (hoofd-
stuk VI) werd er op gewezen dat ook waarnemingen over het biolo-
gisch actieve ACTH werden gedaan. Hoewel beperkt in aantal, vonden 
wij geen verschil in de basale waarden van het biologisch actieve 
ACTH tussen beide groepen. In het commentaar hebben wij uit deze 
combinatie van gegevens de suggestie geopperd dat het ACTH van 
patiënten die paradoxaal reageren op TRH/LRH een relatief hogere 
biologische activiteit heeft. Dit zou er op kunnen wijzen dat het 
ACTH van patiënten uit groep I uit een ander areaal van de hypo-
physe komt dan het ACTH van groep II. Het is immers bekend dat 
het ACTH van de middenkwab een hogere biologische activiteit bezit 
dan het ACTH van de voorkwab. Naast het verschil in de spiegels 
van ACTH tussen beide groepen verschilden zij nog in een ander 
opzicht: de variabiliteit van de corti sol spi egel s in het bloed 
gedurende het etmaal was bij de responders significant geringer. 
Een goede verklaring daarvoor hebben wij niet. Desalniettemin 
wordt het onderscheid tussen beide groepen patiënten met de ziekte 
van Cushing, dat berust op de aan- of afwezigheid van een para-
doxale reactie van ACTH/cortisol na TRH/LRH, versterkt door de 
bovengenoemde verschillen. 
Tot nu toe werden 8 van deze 23 patiënten onderworpen aan chi-
rurgie van de hypophyse: 3 "responders" en 5 "non-responders". 
Wat betreft het resultaat van deze ingreep weten wij dat géén 
van de "responders" klinisch in remissie kwam, terwijl zulks wel 
het geval was bij 4 van de 5 "non-responders". Deze eerste resul-
taten wettigen het vermoeden dat het al dan niet paradoxaal rea-
geren op neuropeptiden als TRH en LRH ook voorspellende waarde 
heeft voor het resultaat van hypophyse-chirurgie. Het bij operatie 
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verkregen hypophyseweefsel werd door Lamberts en Stefanko histo-
chennsch onderzocht. Deze auteurs hadden er op gewezen dat langs 
deze weg morbus Gushing "van het pars intermedia type" door de 
aanwezigheid van neurosecretoire activiteit te onderscheiden is 
van morbus Cushing"van het pars anterior type".De resultaten van 
het onderzoek (zie hoofdstuk VI) rechtvaardigen geenszins de 
conclusie dat patiënten met de ziekte van Cushing die paradoxaal 
reageren op de toediening van TRH/LRH allen van het "pars inter-
media type" zijn, noch dat de ziekte bij die patiënten, die niet 
paradoxaal reageren, van het "pars anterior type" is. 
In hoofdstuk VI hebben wij tenslotte de volgende veronderstel-
ling als onze voorlopige werkhypothese geformuleerd: 
i. Patienten met de ziekte van Cushing die niet paradoxaal 
reageren op de toediening van TRH/LRH zijn waarschijnlijk de pa-
tienten met een (mi ero)adenoom van de ACTH producerende cellen. 
Bij deze patiënten mag men verwachten dat selectieve hypophyse-
chirurgie tot genezing leidt. 
ii. Patienten die een paradoxale toename van ACTH/corti sol 
vertonen op de toediening van TRH/LRH hebben primair een hypotha-
1 ame stoornis die leidt tot hypertrofie of hyperplasie van ACTH 
producerende cellen. Bij deze patiënten kan men in het algemeen 
geen genezing verwachten na selectieve chirurgie van de hypophyse, 
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DANKWOORD. 
Dit proefschrift geeft de resultaten weer van de uitvoering 
van ongeveer 350 "testen". De deskundige medewerking van de ver-
pleegsters van afdeling CIO (hoofd Mevr. C. Willemsen) en van de 
afdeling "Interne staf" (hoofd Mevr. L. Schreppers) was hierbij 
onontbeerlijk. 
De ze^r vele aanvragen voor Radioimmunoassays werden nauw-
keurig verwerkt door de medewerkers van het laboratorium voor 
experimentele en chemische Endocrinologie (hoofd Prof.Dr Th.J. 
Benraad) en van het laboratorium voor Gynaecologie (hoofd Drs 
P.C.W. H o u x ) . 
Bij het verzamelen van de noodzakelijke literatuurgegevens 
was de hulp van de medewerkers van de medische bibliotheek onder 
leiding van de heer E. de Graaff onmisbaar. 
Op de heer C.P. Nicolasen van de medische tekenkamer heb ik 
nooit vergeefs beroep gedaan om, ook op korte termijn, de grafie-
ken te verzorgen. 
De afdeling medische fotografie (hoofd Hr A.T.A. Reijnen) 
maakte dit materiaal drukklaar. 
De vele versies van de verschillende manuscripten werden met 
veel ijver getypt door Mevr. S. v.d. Werf-Morssinkhof, Mevr. W. 
Straten en Mevr. I. Scholten. Mevr. S. v.d. Werf-Morssinkhof 
verzorgde met grote zorg de definitieve versie van dit proef-
schrift. 
Tenslotte verdient Mevr. A. Nijhoff mijn dank wegens haar 
aanvullingen op de tekorten in mijn kennis van de Engelse taal. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd in 1946 geboren. Het 
diploma gymnasium β werd behaald aan het Henric van Veldekecollege 
te Maastricht in 1964. In hetzelfde jaar begon hij met zijn studie 
in de geneeskunde aan de uni ver-si tei t van Nijmegen. Het doctoraal 
examen legde hij af in 1970 en het artsexamen in 1972. Daarna 
begon hij zijn opleiding tot internist bij drs H.B. Benraad in het 
Canisiusziekenhuis te Nijmegen (hoofd opleiding Dr J.H.J. Enneking). 
Deze opleiding werd in 1975 voortgezet aan de universiteitskliniek 
voor inwendige ziekten van het Radboudziekenhuis te Nijmegen 
(destijds hoofd: wijlen Prof.Dr C.L.H. Majoor, huidig hoofd: Prof. 
Dr A. van 't L a a r ) . In 1977 werd hij ingeschreven in het specia­
li stenregi ster . Sindsdien is hij werkzaam op de afdeling Endocri­
nologie (hoofd: Prof.Dr P.W.C. Kloppenborg) van de universiteits­
kliniek voor inwendige ziekten te Nijmegen. 
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STELLINGEN 
1. Paradoxale stijgingen van de bloedspiegels van groeihormoon na 
de toediening van "Luteinizing hormone-releasing hormone"(LRH) 
treden alleen op bij die patiënten met akromegalie, wier groei-
hormoonspi egel s door somatostatine tot normale waarden kunnen 
worden teruggebracht. 
(dit proefschrift) 
2. Paradoxale stijgingen van de spiegels van adrenocorticotropine 
(ACTH) en Cortisol na de toediening van "thyroid stimulating 
hormone-releasing hormone" (TRH) en/of van LRH treden op bij 
+ 40% van de patiënten met de ziekte van Gushing. 
(dit proefschrift) 
3. Onderzoek naar het beloop van de bloedspiegels van Cortisol na 
de toediening van TRH en/of van LRH kan een belangrijk hulp-
middel zijn bij de diagnostiek van de ziekte van Gushing. 
(dit proefschrift) 
4. Bij patiënten met primair hyperaldosteronisme ten gevolge van 
een bijnieradenoom kunnen zich, na de toediening van TRH en/of 
LRH, paradoxale stijgingen van de spiegels van aldosteron voor-
doen, die niet worden voorafgegaan door stijgingen in de concen-
tratie van ACTH. 
(eigen waarneming) 
5. Systematisch onderzoek van familieleden van patiënten met 
multiple endocriene adenomatöse type I (MEA I = syndroom van 
Wermer) is mede daarom niet zinvol omdat deze aandoening niet 
afdoende behandeld kan worden. 
6. Bij patiënten met niet eenvoudig te corrigeren nierarterie-
stenose, is"ex vivo" reconstructie van de nierarterie te ver-
kiezen boven primaire nefrektomie. 
(Stoney RJ, Silane M, Salvatierra 0, 1978, Arch Surg 113, 1272.) 
7. Langdurige behandeling met lage doses van de combinatie van 
cytostatica: cyclophosphamide, methotrexaat en 5 fluoro-
uracil als "adjuvante therapie" bij patiënten met een primair, 
uitgebreid mammacarcinoom, kan het optreden van metastasen in 
de toekomst noch voorkomen, noch uitstellen. 
(Beex LVAM, Pieters GFFM, Smals AGH, Koenders AJM, Benraad ThJ, 
Kloppenborg PWC, 1981, UICC Conference on clinical oncology, 
Lausanne, abstract 1 4 - 0 1 1 2 ) . 
8. De vergroting van de sella turcica bij patiënten met akromega-
lie wordt mogelijk meer door "sel 1a-megali e" dan door druk van 
het hypophyse-adenoom veroorzaakt. 
9. Wanneer een obstetricus besluit tot een mediolaterale episio-
tomie, is het aanbevelenswaard dat deze,bij het kiezen van de 
rechter dan wel de linker zijde, informeert naar de positie 
van het bed in de kamer van de kraamvrouw, zodat zij haar 
bezoek in pijnloze zijligging kan ontvangen. 
10. Bij een promotie wordt van de doctorandus verwacht dat hij 
naast de stellingen die over zijn vakgebied en over zijn thesis 
gaan, een of meer "algemene" stellingen verdedigt om te doen 
vermoeden dat hij de laatste jaren ook nog aan iets anders 
gewerkt heeft. 
11. De partij van de engelse hoorn aan het eind van het derde deel 
van Berlioz's "Symphonie fantastique" is een toppunt van 
muzikale uitbeelding van desolatie. 
12. Het pignon met zes in plaats van vijf tandwielen verschaft hem 
die zowel in het hooggebergte als "op het vlakke" fietst, 
aanzienlijk meer mogelijkheden. 
(eigen waarneming) 
13. De promotor heeft altijd 't laatste woord. 
(eigen waarneming) 
G.F.F.M. Pieters 


